Podcasts about in silico

I had the chance to speak with Petrina Kamiya, Global Head of AI Platforms and VP at Insilico Medicine, as well as President of Insilico Medicine Canada. Insilico Medicine is what Petrina calls a “tech bio”—developing both AI platforms and therapeutic assets, with a flexible model licensing both. Their pharma.ai platform was created to address challenges in drug discovery all the way from target identification to the clinic. In just a few years, they've gone from having two core products to a suite of about 12, all built with a heavy emphasis on validation.When I think about AI in drug development, I think about all the failures in clinical trials. I've always wondered: are the molecules themselves to blame, or is the reason for so many failures rooted in the aspects that surround their testing—like patient selection, procedures, or trial design? Petrina confirmed that the two biggest reasons for failure are safety and efficacy. Many failures are turn out to be preclinical issues—either the wrong target was selected, or the molecule causes unintended side effects. AI and machine learning are being used to better predict both, by identifying high-confidence disease targets and designing safer molecules.But predicting toxicity is still a major challenge. There are models at every stage—from in silico predictions to in vitro and animal models—but each layer adds complexity, and good data to train AI models is notoriously hard to come by. A lot of data around failed molecules never makes it into the public domain because it's proprietary. That means valuable insights about toxicity are often lost, though some substructures known to be problematic are at least captured in public databases. I realize that companies need a return on their investment and even failure data has competitive value. But you have to wonder how much money is wasted chasing dead ends that could have been avoided.The other question I always have is about the mechanics of drug binding. Most approaches focus on the active site—the orthosteric site—where the protein normally interacts with its natural ligand. I asked about the possibility of other strategies like allosteric binding (where a drug binds somewhere else on the protein to inhibit function). Petrina validated that idea along with degraders, which are molecules designed to bring a protein into contact with the cellular machinery that destroys it. These newer modalities, including molecular glues, offer ways to selectively disable problem proteins without relying on traditional binding.Nothing is straightforward. Allosteric sites can offer greater selectivity, which could reduce toxicity. But finding those sites is incredibly difficult because proteins are dynamic and mobile. It's not just about structure; it's about motion within the protein itself and context.The body's backup systems—redundant pathways, mutations, and rescue mechanisms—can undermine even well-designed drugs. This is especially relevant in oncology. Proteins like KRAS have so many variants that it's not enough to design one effective inhibitor—you often need a panel of drugs to address different mutations. Petrina noted that the human body has many fallback mechanisms, which makes targeting disease pathways more difficult but also explains why drugs that seem perfect in vitro don't always deliver in the clinic.Not subscribed? Let's fix that. No spam, just good content wherever I find it.Getting back to clinical trials, AI is mostly being applied operationally right now—to optimize patient selection, identify clinical sites with the right patient profiles, and monitor for trial reporting issues. The big advantage is in stratifying patients to improve the signal-to-noise ratio. As Petrina noted, sometimes a drug works for a subset of patients, but that signal is lost in the broader trial data. That resonated with my previous interview with Kurt Mussina who used AI to identify ideal site locations based on logistics and patient demographics—a very practical, high-impact use of the technology.What if we could recover some therapies that have previously failed because it wasn't tested on the right people? AI could help salvage and reposition those compounds by uncovering hidden signals in the data. You have to believe that improvements in AI will find a few lost nuggets—digging back through data with better tools to find value that's already there.Developing therapies aren't the only application for new molecule discovery. Insilico is also working with companies in the herbicide space, and as Petrina explained, discovering herbicides isn't all that different from designing drugs for people. You still need target specificity, safety, and cost-efficiency—but at an even greater scale of production. If people or animals are exposed, or if the herbicide lingers in the environment, it has to meet a high safety bar.The unique challenge here is complexity and scale. It comes down to economics. We may spare no expense to extend a human life with doses in the milligram range. In agriculture, you're looking for a simple compound that is cheap, can be produced in massive quantities, and can be stored in almost any conditions. It's a new set of constraints.AI in discovery isn't about magic. It's about building better foundations—more accurate models, more validated data, and more thoughtful decision-making—to improve every step from discovery to clinical success.Your deepest insights are your best branding. I'd love to help you share them. Chat with me about custom content for your life science brand. Or visit my website. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit cclifescience.substack.com

人工智慧（AI）如何改變藥物開發？藥物開發從臨床前研究到臨床試驗，通常需要超過十年時間和數十億美元的投資，卻仍有高達九成的藥物在臨床試驗中失敗。這些挑戰，現在 AI 正在各種方面掀起革命。在這系列節目中，我們將探討 AI 在藥物開發領域中的應用，並介紹在這個快速發展的領域中工作的專家。 本集為《AI 藥物開發系列》的第二集。在本集節目中，我們特別邀請到了陽明交大的兼任助理教授林彥竹，他同時也是英科智能 Insilico Medicine 台灣區的前 CEO*。他將分享他從臺大藥學院畢業後，如何跨足至瑞士聯邦理工學院，並進入英科智能深耕 AI 藥物開發的豐富經歷，以及他對於 AI 在生醫領域未來發展的看法。 此外，我們也探討英科智能的平台如何加速藥物篩選的過程，從而大幅縮短從實驗室到臨床的時間。希望大家將能更清楚地了解 AI 如何改變傳統藥物研發流程，以及這場科技革命如何影響生醫領域的未來。 *註: 講者受訪時仍任職於英科智能  

This week's episode of the Generative AI Meetup Podcast, hosted by Mark and Shashank, dives into the riveting discussions from the recent Don't Die Summit. The duo shares their firsthand experiences, including an interview with Alex Zhavoronkov, CEO of Insilico, who discusses the groundbreaking generative AI model, Presses GPT, aimed at extending human healthspan. Also featured are insights into the newly announced OpenAI o1 model, its capabilities in enhancing AI reasoning, and a look into the latest Apple Intelligence features and iPhone 16. Join us for a comprehensive overview of AI's expanding role in health and technology.

This week we get into AI in health care, generative and personalized medicine, the cure for cancer and why CoVID helped supercharge that and how AI is helping us live longer, healthier lives. Alex Zhavoronkov, the founder of AI-MedTech player Insilico joins us on TF to talk how health care is going to radically change over the next decade or two. An amazing deep dive. Don't miss it! Future health care trends with Alex Zhavoronkov Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leading clinical-stage biotechnology company developing next-generation artificial intelligence and robotics platforms for drug discovery. He is also the founder and Chief Longevity Officer of Deep Longevity, Inc, a spin-off of Insilico Medicine developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and life insurance industry. In 2020 Deep Longevity was acquired by Endurance Longevity (HK: 0575).Since 2014 he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership, Insilico raised over $415 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 11 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule.Prior to founding Insilico, he worked in senior roles at ATI Technologies (GPU company acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 160 peer-reviewed research papers, and 2 books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Macmillan, 2013). He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022), the world's largest event on aging in the pharmaceutical industry. He did his two bachelor degrees at Queen's University in Canada, masters in biotechnology at Johns Hopkins, and PhD in biophysics at MSU. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging. See more podcasts here, and see more about The Futurists here.

This week we get into AI in health care, generative and personalized medicine, the cure for cancer and why CoVID helped supercharge that and how AI is helping us live longer, healthier lives. Alex Zhavoronkov, the founder of AI-MedTech player Insilico joins us on TF to talk how health care is going to radically change over the next decade or two. An amazing deep dive. Don't miss it! Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leading clinical-stage biotechnology company developing next-generation artificial intelligence and robotics platforms for drug discovery. He is also the founder and Chief Longevity Officer of Deep Longevity, Inc, a spin-off of Insilico Medicine developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and life insurance industry. In 2020 Deep Longevity was acquired by Endurance Longevity (HK: 0575).Since 2014 he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership, Insilico raised over $415 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 11 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule.Prior to founding Insilico, he worked in senior roles at ATI Technologies (GPU company acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 160 peer-reviewed research papers, and 2 books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Macmillan, 2013). He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022), the world's largest event on aging in the pharmaceutical industry. He did his two bachelor degrees at Queen's University in Canada, masters in biotechnology at Johns Hopkins, and PhD in biophysics at MSU. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

This week we get into AI in health care, generative and personalized medicine, the cure for cancer and why CoVID helped supercharge that and how AI is helping us live longer, healthier lives. Alex Zhavoronkov, the founder of AI-MedTech player Insilico joins us on TF to talk how health care is going to radically change over the next decade or two. An amazing deep dive. Don't miss it!

Designing a successful PCR assay is all about selecting the right primers to deliver the sensitivity and selectivity for which PCR is known for. But anyone that's designed an assay themselves will know that doing so successfully is a lot harder it sounds. We're joined by two PCR assay design pros for this episode. Kimi Soohoo Ong, and Dr. Rounak Feigelman, both from Thermo Fisher Scientific, shine a light on the many factors that must be considered to design a winning PCR assay. From the level of fragmentation of nucleic acids in the sample, to what other species' genomes that may be present in the sample, to what the sample matrix may contain, to the PCR master mix being used, if multiplexing is required, to what assay controls will be, and more!  These two practiced bioinformaticians cover these challenges and then tell us how their team overcomes challenges to develop winning assays for both qPCR and dPCR applications. Our conversation uncovers the level of skill and artistry that goes into this craft. As always, you get to learn a bit more about our guests' backgrounds and career paths in the Cassie's Career Corner portion of the interview. They share how they both chose a bioinformatics path over wet lab work, while also acknowledging how important the wet lab work is to what they do. They also share some great advice and resources for anyone looking to explore a career in bioinformatics. Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

With the 2024 J.P. Morgan Healthcare Conference underway, MM+M's Marc Iskowitz provides an update from on the ground in San Francisco. Digital Editor Jack O'Brien talks with Insilico Medicine President Michelle Chen about the company's ongoing work to bring generative AI's capabilities to the world of clinical research. Senior Reporter Lecia Bushak talks about the Food and Drug Administration's historic move to give Florida the ability to import medications from Canada at much lower prices than in the U.S.Eli Lilly's LillyDirect website launch marks a direct-to-consumer push for GLP-1 drugs like Zepbound, we dive into Defense Secretary Lloyd Austin's controversial prostate cancer treatment saga and examine the brands and influencers toasting to Dry January. Music by Sixième Son.Follow us: @mmmnewsTo read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

How is academia fostering research that later turns into startup companies? What are new computational powers bringing to in silico drug design? And what is MoveableType methodology and why should pharma be excited about it? We will learn those answers and more in this episode with Lance Westerhoff, President and General Manager of QuantumBio. QuantumBio is a biotech startup operating in the vast field of drug discovery and molecular design. As President and GM, Lance oversees QuantumBio's day-to-day management including the research, development, and deployment of advanced technology, as well as strategic partnerships and business development. Lance earned his PhD in Chemistry at Penn State University, and he is an entrepreneur, computational biochemist, and published scientist with projects involving the synergistic application of quantum mechanics and molecular mechanics in the life and pharmaceutical sciences. QuantumBio recently earned a Small Business Innovation Research (SBIR) grant from the NIH to run calculations for their MovableType methodology research, which they will be working with Oracle on that research project, and we talk about that and much more in this episode.  

Discover how Insilico Medicine is accelerating drug discovery using Generative AI in the latest episode of the AWS Health Innovation Podcast. CEO Alex Zhavoronkov joins AWS' Dr. Yin He to discuss their journey and how they are accelerating drug development.

Alex Zhavoronkov is our first guest to make a repeat appearance, having first joined us in episode 12, last November. We are delighted to welcome him back, because he is doing some of the most important work on the planet, and he has some important news.In 2014, Alex founded Insilico Medicine, a drug discovery company which uses artificial intelligence to identify novel targets and novel molecules for pharmaceutical companies. Insilico now has drugs designed with AI in human clinical trials, and it is one of a number of companies that are demonstrating that developing drugs with AI can cut the time and money involved in the process by as much as 90%. Selected follow-ups:https://insilico.com/ARDD 2023: https://agingpharma.org/Topics addressed in this episode include:*) For the first time, an AI-generated molecule has entered phase 2 human clinical trials; it's a  candidate treatment for IPF (idiopathic pulmonary fibrosis)*) The sequence of investigation: first biology (target identification), then chemistry (molecule selection), then medical trials; all three steps can be addressed via AI*) Pros and cons of going after existing well-known targets (proteins) for clinical intervention, versus novel targets*) Pros and cons of checking existing molecules for desired properties, versus imagining (generating) novel molecules with these properties*) Alex's experience with generative AI dates back to 2015 (initially with GANs - "generative adversarial networks")*) The use of interacting ensembles of different AI systems - different generators, and different predictors, allocating rewards*) The importance of "diversity" within biochemistry*) A way in which Insilico follows "the Apple model"*) What happens in Phase 2 human trials - and what Insilico did before reaching Phase 2*) IPF compared with fibrosis in other parts of the body, and a connection with aging*) Why probability of drug success is more important than raw computational speed or the cost of individual drug investigations*) Recent changes in the AI-assisted drug development industry: an investment boom in the wake of Covid, spiced-up narratives devoid of underlying substance, failures, downsizing, consolidation, and improved understanding by investors and by big pharma*) The AI apps created by Insilico can be accessed by companies or educational institutes*) Insilico research into quantum computing: this might transform drug discovery in as little as two years*) Real-world usage of quantum computers from IBM, Microsoft, and Google*) Success at Insilico depended on executive management task reallocation*) Can Longevity Escape Velocity be achieved purely by pharmacological interventions?*) Insilico's Precious1GPT approach to multimodal measurements of biological aging, and its ability to suggest new candidate targets for age-associated diseases: "one clock to rule them all"*) Reasons to mentally prepare to live to 120 or 150*) Hazards posed to longevity research by geopolitical tensions*) Reasons to attend ARDD in Copenhagen, 28 Aug to 1 Sept*) From longevity bunkers to the longevity dividendMusic: Spike Protein, by Koi Discovery, available under CC0 1.0 Public Domain Declaration

In this episode of Life Science Success my Guest is Alex Zhavoronkov.  Alex is the CEO Insilico Medicine an AI-powered drug discovery company. Insilico Medicine has progressed three internally-derived assets into human clinical trials. Insilico Medicine has discovered over 30 other programs in different stages. Insilico Medicine incorporates three engines in their platform: biology, chemistry, and clinical. They generate normal molecules with desired properties using 42 generative engines. They have a system that predicts clinical trials outcomes. Insilico Medicine's main strategy is partnering with pharma companies at the preclinical candidate stage. They value patient first, relentless innovation, and transparency and integrity. Alex's biggest concern is human tendency to prioritize unimportant things over important ones. Alex is excited about large language models, multimodal generative AI, robotics, and quantum computing.

In which Alex Zhavoronkov, founder and CEO of Insilico Medicine, discusses how AI can accelerate drug R&D, from target identification to clinical trials. He also shares his own path from computer science to biotech, explains how Insilico's business model has evolved, and gives advice on leading interdisciplinary teams.

From content writing, to providing human-like responses in chatbots, and to even coding. Generative AI has made its potential known to the world with the introduction of ChatGPT.  But besides, did you know that generative AI can be used in the process of drug discovery as well?  Today we speak with Insilico Medicine, a clinical stage AI driven drug discovery company that is delivering breakthrough solutions to discover and develop medicines in areas such as cancer, immunity and ageing. The company was selected by NVIDIA as one of the top 5 AI companies for its potential for social impact back in 2017. But how does it work, and what does a new drug discovery mean for the company? Separately, Insilico Medicine had also signed a strategic research collaboration with pharmaceutical giant Sanofi in a deal worth up to US$1.2 billion last November. So, what is the status right now? On Under the Radar, Drive Time's finance presenter Chua Tian Tian posed these questions to Dr Alex Zhavoronkov, CEO of Insilico Medicine. See omnystudio.com/listener for privacy information.

TracklistMade By Pete, Just Her - The Tide (Billka Remix)East Cafe - When Chaos EndsSebastian Haas, - Endless NightsQuivver, Olivier Giaccomotto - Snailblazer [Selador]Teleport X - Just Want to Know (Lio Q, Nicolas Leonelli dub mix)Kebin Van Reeken - HypnotiseToledo - Galatari (Dave Walker Remix) [Forensic Records]D.J. Macintyre, J Lauda Nomas - Castle GardenVes Racemus - Nature Of Order [Layer Caked Records]Ruben Karapetyan - Metorite (Jerome Isma-ae Remix)In Silico - Animus

#ai #generativeai #drugdiscovery #pharma In this episode of CXOTalk, we have the pleasure of speaking with Dr. Alex Zhavoronkov, the founder and CEO of Insilico Medicine.Insilico Medicine uses artificial intelligence to enhance drug discovery. By combining generative adversarial networks (GANs), reinforcement learning, and other AI techniques, Insilico streamlines the design, synthesis, and testing of new molecules. Their approach has garnered attention, raising $400 million in funding so far.Dr. Zhavoronkov shares insights into Insilico's goals, such as the accelerated development and testing of small molecules targeting specific diseases. We also explore how their software impacts pharmaceutical R&D by enabling researchers to investigate new targets, design molecules with certain properties, and potentially predict the outcomes of clinical trials.Join us as we discuss the evolving landscape of pharmaceuticals and how generative AI can help discover new treatments for chronic diseases and promote a healthier future.The conversion covers these topics:► Early generative AI experiments & adversarial networks► Generative AI in molecular drug design► Advancements: AI techniques & reinforcement learning► Insilico Medicine's funding journey & challenges► Unique challenges in AI-based drug discovery► First validation of AI-generated molecules► Software for chemistry & biology applications► Traditional vs. Insilico Medicine's approach► Pharma challenges: high costs, low novelty, and diminishing returns► Potential billion-dollar payout for successful Phase II drugs► AI in drug development can increase success probability► Early partnerships with large pharma and lessons learned► Decision to stop doing pilots with big pharma companies► Generative AI and public data► De-biasing pharmaceutical research► Automating the workflow and quality control► Reinforcing generative AI with real experiments► “Drug discovery is brutal”► Drug discovery democratization► AI in medical writing► IP risks and generative AI► AI and robotics to prevent agingVisit our website for the audio podcast: https://www.cxotalk.com/episode/future-of-drug-discovery-generative-ai-in-pharma-and-medicineSubscribe to the newsletter: https://www.cxotalk.com/subscribeCheck out our upcoming live shows: https://www.cxotalk.comAlex Zhavoronkov, Ph.D. is the founder and CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. He is also the founder of Deep Longevity, Inc, a spin-off of Insilico Medicine developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and life insurance industry. In 2020, Deep Longevity was acquired by Endurance Longevity (HK: 0575). Beginning in 2015, he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered applications of deep learning technologies for the prediction of human biological age using multiple data types, and transferred learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership, Insilico has raised over $400 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 11 preclinical candidates, and has generated positive topline Phase 1 data in human clinical trials with an AI-discovered novel target and AI-designed novel molecule for idiopathic pulmonary fibrosis that received Orphan Drug Designation from the FDA and is nearing Phase 2 clinical trials. Insilico also recently announced that its generative AI-designed drug for COVID-19 and related variants was approved for clinical trials.Prior to founding Insilico, he worked in senior roles at ATI Technologies (a GPU company acquired by AMD in 2006), NeuroGNeuroinformatics, and the Biogerontology Research Foundation. Since 2012, he has published over 150 peer-reviewed research papers, and 2 books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Macmillan, 2013). He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and founded and co-chairs the Annual Aging Research and Drug Discovery conference, the world's largest event on aging in the pharmaceutical industry. He is an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

It may feel like generative AI technology suddenly burst onto the scene over the last year or two, with the appearance of text-to-image models like Dall-E and Stable Diffusion, or chatbots like ChatGPT that can churn out astonishingly convincing text thanks to the power of large language models. But in fact, the real work on generative AI has been happening in the background, in small increments, for many years. One demonstration of that comes from Insilico Medicine, where Harry's guest this week, Alex Zhavoronkov, is the co-CEO. Since at least 2016, Zhavoronkov has been publishing papers about the power of a class of AI algorithms called generative adversarial networks or GANs to help with drug discovery. One of the main selling points for GANs in pharma research is that they can generate lots of possible designs for molecules that could carry out specified functions in the body, such as binding to a defective protein to stop it from working. Drug hunters still have to sort through all the possible molecules identified by GANs to see which ones will actually work in vitro or in vivo, but at least their pool of starting points can be bigger and possibly more specific.Zhavoronkov says that when Insilico first started touting this approach back in the mid-2010s, few people in the drug business believed it would work. So to persuade investors and partners of the technology's power, the company decided to take a drug designed by its own algorithms all the way to clinical trials. And it's now done that. This February the FDA granted orphan drug designation to a small-molecule drug Insilico is testing as a treatment for a form of lung scarring called idiopathic pulmonary fibrosis. Both the target for the compound, and the design of the molecule itself, were generated by Insilico's AI. The designation was a big milestone for the company and for the overall idea of using generative models in drug discovery. In this week's interview, Zhavoronkov talks about how Insilico got to this point; why he thinks the company will survive the shakeout happening in the biotech industry right now; and how its suite of generative algorithms and other technologies such as robotic wet labs could change the way the pharmaceutical industry operates.For a full transcript of this episode, please visit our episode page at http://www.glorikian.com/podcast Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.That's it! Thanks so much.

Citeline managing editor Brain Yang discusses with Insilico Co-CEO and Head of Drug Discovery Feng Ren on artificial intelligence-assisted drug discovery for idiopathic pulmonary fibrosis. https://scrip.pharmaintelligence.informa.com/SC147940/AI-ChatGPT-And-The-Future-Of-Drug-Discovery-China-Biotech-CEO-Podcast-WIth-Insilicos-CoCEO

For episode 7, we chat with Alex Zhavoronkov, Founder & CEO at Insilico Medicine.Stay tuned and find out which partnerships are crucial for very early stages in learning and gaining experience in drug discovery. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full episode transcript, click here.  Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.

Petrina Kamya, head of AI platforms at Insilico Medicine, talks to Andrew Brosnan, principal analyst in AI and Applied Intelligence at Omdia, to take a deep dive into the intricacies of AI-powered drug discovery.

Today's podcast is dedicated to In Silico methods including read-across and (Q)SAR approaches. The adoption of the European Cosmetic Regulation 1223/2009 has contributed to the development of alternative methods and tests to assess the hazards of new substances without animal testing. Join our French Intertek Assuris experts, Marie Duigou and Déborah Mitjans, as they talk about In Silico methods focusing on cosmetic ingredients, EU legislation & much more. intertek.comFollow us on Twitter and LinkedIn

This episode discusses progress at Insilico Medicine, the AI drug development company founded by our guest, longevity pioneer Alex Zhavoronkov.1.20 In Feb 2022, Insilico got an IPF drug into phase 1 clinical trials: a first for a wholly AI-developed drug1.50  Insilico is now well-funded; its software is widely used in the pharma industry2.30 How drug development works. First you create a hypothesis about what causes a disease4.00 Pandaomics is Insilico's software to generate hypotheses. It combines 20+ AI models, and huge public data repositories6.00 This first phase is usually done in academia. It usually costs $ billions to develop a hypothesis. 95% of them fail6.50 The second phase is developing a molecule which might treat the disease7.15 This is the job of Insilico's Chemistry 42 platform7.30 The classical approach is to test thousands of molecules to see if they bind to the target protein7.50 AI, by contrast, is able to "imagine" a novel molecule which might bind to it8.00 You then test 10-15 molecules which have the desired characteristics8.20 This is done with a variety of genetic algorithms, Generative Adversarial Networks (GANs), and some Transformer networks8.35 Insilico has a “zoo” of 40 validated models10.40 Given the ten-fold improvement, why hasn't the whole drug industry adopted this process?10.50 They do all have AI groups and they are trying to change, but they are huge companies, and it takes time11.50 Is it better to invent new molecules, or re-purpose old drugs, which are already known to be safe in humans?13.00 You can't gain IP with re-purposed drugs: either somebody else “owns” them, or they are already generic15.00 The IPF drug was identified during aging research, using aging clocks, and a deep neural net trained on longitudinal data17.10 The third phase is where Insilico's other platform, InClinico, comes into play17.35 InClinico predicts the results of phase 2 (clinical efficacy) trials18.15 InClinico is trained on massive data sets about previous trials19.40 InClinico is actually Insilico's oldest system. Its value has only been ascertained now that some drugs have made it all the way through the pipeline22.05 A major pharma company asked Insilico to predict the outcome of ten of its trials22.30 Nine of these ten trials were predicted correctly23.00 But the company decided that adopting this methodology would be too much of an upheaval; it was unwilling to rely on outsiders so heavily24.15 Hedge funds and banks have no such qualms24.25 Insilico is doing pilots for their investments in biotech startups26.30 Alex is from Latvia originally, studied in Canada, started his career in the US, but Insilico was established in Hong Kong. Why?27.00 Chinese CROs, Contract Research Organisations, enable you to do research without having your own wetlab 28.00 Like Apple, Insilico designs in the US and does operations in China. You can also do clinical studies there28.45 They needed their own people inside those CROs, so had to be co-located29.10 Hong Kong still has great IP protection, financial expertise, scientific resources, and is a beautiful place to live29.40 Post-Covid, Insilico also had to set up a site in Shanghai30.35 It is very frustrating how much opposition has built up against international co-operation32.00 Anti-globalisation ideas and attitudes are bad for longevity research, and all of biotech33.20 Insilico has all the data it needs. Its bottleneck is talent35.00 Another requirement is co-operation from governments and regulators, who often struggle to sort the chaff from the wheat in self-proclaimed AI companies37.00 Longevity research is the most philanthropic activity in the world37.30 Longevity Medicine Course is available to get clinical practitioners up to speed with the sector

Calum and David reflect on their involvement in two recent conferences, one in Riyadh, and one in Dublin. Each conference highlighted a potential disruption in a major industry: a country with large ambitions in the AI space, and a new foundation in the longevity space.00.00 A tale of two cities, two conferences, two industries00.44 First, the 2nd Saudi Global AI Conference01.03 Vision 203001.11 Saudi has always been a coalition between the fundamentalist Wahhabis and the Royal Family01.38 The King chooses reform in the wake of 9/1102.07 Mohamed bin Salman appointed Crown Prince, who embarks on reform02.28 The partial liberation of women, and the fundamentalists side-lined03.10 The “Sheikhdown” in 201703.49 The Khashoggi affair and the Yemen war lead to Saudi being shunned04.26 The West is missing what's going on in Saudi05.00 Lifting the Saudi economy's reliance on petrochemicals05.27 AI is central to Vision 203006.00 Can Saudi become one of the world's top 10 or 15 AI countries?06.20 The AI duopoly between the US and China is so strong, this isn't as hard as you might think06.55 Saudi's advantages07.22 Saudi's disadvantages07.54 The goal is not implausible08.10 The short-term goals of the conference. A forum for discussions, deals, and trying to open the world's eyes09.45 Saudi is arguably on the way to becoming another Dubai. Continuation and success are not inevitable, but it is encouraging11.00 Fastest-growth country in the G20, with an oil bonanza11.25 The proposed brand-new city of Neom with The Line, a futuristic environment13.07 The second conference: the Longevity Summit in Dublin13.48 A new foundation announced14.05 Reports updating on progress in longevity research around the world14.20 A dozen were new and surprising. Four examples…14.50 1. Bats. A speaker from Dublin discussed why they live so long – 40 years – and what we can learn from that15.55 2. Parabiosis on steroids. Linking the blood flow of two animals suggests there are aging elements in our blood which can be removed17.50 3. Using AI to develop drugs. Companies like Exscientia and Insilico. Cortex Discovery is a smaller, perhaps more nimble player19.40 4. Hevolution, a new longevity fund backed with up to $1bn of Saudi money per year for 20 years22.05 As Aubrey de Grey has long said, we need engineering as much as research22.40 Aubrey thinks aging should be tackled by undoing cell damage rather than changing the human metabolism24.00 Three phases of his career. Methuselah. SENS. New foundation25.00 Let's avoid cancer, heart disease and dementias by continually reversing aging damage26.00 He is always itchy to explore new areas. This led to a power struggle within SENS, which he lost27.00 What should previous SENS donors do now?27.15 The rich crypto investors who have provided large amounts to SENS are backing the new foundation28.30 One of the new foundation's investment areas will be parabiosis28.55 Cryonics will be another investment area29.15 Lobbying legislators will be another29.50 Robust Mouse Rejuvenation will be the initial priority30.50 Pets may be the animal models whose rejuvenation breaks humanity's “trance of death”31.05 David has been appointed a director the new foundation31.50 The other directors33.05 An exciting futureAudio engineering by Alexander Chace.Music: Spike Protein, by Koi Discovery, available under CC0 1.0 Public Domain DeclarationThe conference websites: https://globalaisummit.org/ and https://longevitysummitdublin.com/For more about the podcast hosts, see https://calumchace.com/ and https://dw2blog.com/

Check out my free video series about what's missing in AI and Neuroscience Support the show to get full episodes and join the Discord community. Gaute Einevoll is a professor at the University of Oslo and Norwegian University of Life Sciences. Use develops detailed models of brain networks to use as simulations, so neuroscientists can test their various theories and hypotheses about how networks implement various functions. Thus, the models are tools. The goal is to create models that are multi-level, to test questions at various levels of biological detail; and multi-modal, to predict that handful of signals neuroscientists measure from real brains (something Gaute calls "measurement physics"). We also discuss Gaute's thoughts on Carina Curto's "beautiful vs ugly models", and his reaction to Noah Hutton's In Silico documentary about the Blue Brain and Human Brain projects (Gaute has been funded by the Human Brain Project since its inception). Gaute's website.Twitter: @GauteEinevoll.Related papers:The Scientific Case for Brain Simulations.Brain signal predictions from multi-scale networks using a linearized framework.Uncovering circuit mechanisms of current sinks and sources with biophysical simulations of primary visual cortexLFPy: a Python module for calculation of extracellular potentials from multicompartment neuron models.Gaute's Sense and Science podcast. 0:00 - Intro 3:25 - Beautiful and messy models 6:34 - In Silico 9:47 - Goals of human brain project 15:50 - Brain simulation approach 21:35 - Degeneracy in parameters 26:24 - Abstract principles from simulations 32:58 - Models as tools 35:34 - Predicting brain signals 41:45 - LFPs closer to average 53:57 - Plasticity in simulations 56:53 - How detailed should we model neurons? 59:09 - Lessons from predicting signals 1:06:07 - Scaling up 1:10:54 - Simulation as a tool 1:12:35 - Oscillations 1:16:24 - Manifolds and simulations 1:20:22 - Modeling cortex like Hodgkin and Huxley

In this episode, co-hosts Calum Chace and David Wood explore a number of recent developments in AI - developments that are rapidly changing what counts as "state of the art" in AI.00.05: Short recap of previous episodes00.20: A couple of Geoff Hinton stories02.27: Today's subject: the state of AI today02.53: Search03.35: Games03.58: Translation04.33: Maps05.33: Making the world understandable. Increasingly07.00: Transformers. Attention is all you need08.00: Masked language models08.18: GPT-2 and GPT-308.54: Parameters and synapses10.15: Foundation models produce much of the content on the internet10.40: Data is even more important than size11.45: Brittleness and transfer learning13.15: Do machines understand?14.05: Human understanding and stochastic parrots15.27: Chatbots16.22: Tay embarrasses Microsoft16.53: Blenderbot17.19: Far from AGI. LaMDA and Blaise Lemoine18.26: The value of anthropomorphising19.53: Automation20.25: Robotic Process Automation (RPA)20.55: Drug discovery21.45: New antibiotics. Discovering Halicin23.50: AI drug discovery as practiced by Insilico, Exscientia and others25.33: Eroom's Law26.34: AlphaFold. How 200m proteins fold28.30: Towards a complete model of the cell29.19: Analysis30.04: Air traffic controllers use only 10% of the data available to them30.36: Transfer learning can mitigate the escalating demand for compute power31.18: Next up: the short-term future of AIAudio engineering by Alexander Chace.Music: Spike Protein, by Koi Discovery, available under CC0 1.0 Public Domain DeclarationFor more about the podcast hosts, see https://calumchace.com/ and https://dw2blog.com/

In 2010 filmmaker Noah Hutton set out to document the work of visionary, and TED Talk supernova, neuroscientist Henry Markram, as he turns his frustration with his chosen field's vested interest in maintaining a status quo attitude. With time elapsing and millions of dollars on the line, this compelling and fascinating documentary, IN SILICO, explores an audacious 10-year quest to simulate the entire human brain on supercomputers. Along the way, IN SILICO reveals the profound beauty of tiny mistakes and bold predictions — a controversial space where scientific process meets ego, and where the lines between objectivity and ambition blur. Director, producer, writer, cinematographer, editor and composer Noah Hutton (Lapsis, Crude Independence, Deep Time) joins us for an entertaining conversation on the visionary / foolhardy project to map and replicate the most complex organism / data processor in the known universe as well as Hutton's own personal and professional determination to chronicle the jagged trajectory of this groundbreaking enterprise. For updates and screenings go to: insilicofilm.com For more on the work of Noah Hutton go to: couple3films.com

Check out my free video series about what's missing in AI and Neuroscience Support the show to get full episodes and join the Discord community. Noah Hutton writes, directs, and scores documentary and narrative films. On this episode, we discuss his documentary In Silico. In 2009, Noah watched a TED talk by Henry Markram, in which Henry claimed it would take 10 years to fully simulate a human brain. This claim inspired Noah to chronicle the project, visiting Henry and his team periodically throughout. The result was In Silico, which tells the science, human, and social story of Henry's massively funded projects - the Blue Brain Project and the Human Brain Project. In Silico website.Noah's website.Twitter: @noah_hutton. 0:00 - Intro 3:36 - Release and premier 7:37 - Noah's background 9:52 - Origins of In Silico 19:39 - Recurring visits 22:13 - Including the critics 25:22 - Markram's shifting outlook and salesmanship 35:43 - Promises and delivery 41:28 - Computer and brain terms interchange 49:22 - Progress vs. illusion of progress 52:19 - Close to quitting 58:01 - Salesmanship vs bad at estimating timelines 1:02:12 - Brain simulation science 1:11:19 - AGI 1:14:48 - Brain simulation vs. neuro-AI 1:21:03 - Opinion on TED talks 1:25:16 - Hero worship 1:29:03 - Feedback on In Silico

La neurociencia computacional es un campo de investigación en alza que pretende recrear de forma virtual las redes o conexiones neuronales y sus interacciones en nuestro cerebro. Estos modelos no solo permitirán conocer su funcionamiento, sino también ayudar a las máquinas para que puedan procesar más y mejor la información, aprender, adaptarse a su entorno y comportarse de una forma más humana. Hemos entrevistado a Humberto Bustince Sola, catedrático de Ciencia de la Computación e Inteligencia Artificial de la Universidad Pública de Navarra. Ha pasado más de una década de su lanzamiento y José Luis Trejo nos ha hablado del estado en que se encuentra el proyecto europeo Cerebro Humano. Recientemente se estrenado el documental “In Silico”, de Noah Hutton, que explora un viaje de 10 años en la búsqueda de simular el cerebro humano en superordenadores. Ana Iglesias nos ha informado del proyecto europeo “Island Life” concedido al CSIC para el estudio de la biodiversidad en las islas, amenazada por el cambio global y la introducción de especies invasoras. Con testimonios de Anna Traveset del Instituto Mediterráneo de Estudios Avanzados. Bernardo Herradón nos ha hablado de nueva edición que está preparando del curso de divulgación "Los avances de la Química y su impacto en la sociedad", con ponentes muy destacados y temas muy interesantes. Esther García nos ha informado del proyecto PIM, una escuela de matemáticas para jóvenes dependiente del ICMAT, el Instituto de Ciencias Matemáticas, con el objetivo de fomentar vocaciones tempranas. Abrirá sus puertas en octubre aunque ya han comenzado las preinscripciones. Con testimonios de Eva Elduque y Moisés Herradón. Hemos reseñado los libros “Museo Nacional de Ciencias Naturales. Nuestra investigación al alcance de tu mano”, coordinado por Cristina Cánovas Fernández; "Embarazos y partos de las reinas de España. de Isabel Católica a doña Letizia", de Pedro Gargantilla y Berta Martín Cabrejas (La esfera de los libros); "Mira quien habla. Cosas que dicen los animales", de Francesca Buoninconti (Alianza editorial); "Orden, desorden y complejidad. Un camino hacia el origen de la vida", de Manuel J. Tello (Catarata); y “Una antropóloga en la Luna. Las historias más sorprendentes de la especie humana", de Noemí Villaverde (Oberón). Escuchar audio

La neurociencia computacional es un campo de investigación en alza que pretende recrear de forma virtual las redes o conexiones neuronales y sus interacciones en nuestro cerebro. Estos modelos no solo permitirán conocer su funcionamiento, sino también ayudar a las máquinas para que puedan procesar más y mejor la información, aprender, adaptarse a su entorno y comportarse de una forma más humana. Hemos entrevistado a Humberto Bustince Sola, catedrático de Ciencia de la Computación e Inteligencia Artificial de la Universidad Pública de Navarra. Ha pasado más de una década de su lanzamiento y José Luis Trejo nos ha hablado del estado en que se encuentra el proyecto europeo Cerebro Humano. Recientemente se estrenado el documental “In Silico”, de Noah Hutton, que explora un viaje de 10 años en la búsqueda de simular el cerebro humano en superordenadores. Ana Iglesias nos ha informado del proyecto europeo “Island Life” concedido al CSIC para el estudio de la biodiversidad en las islas, amenazada por el cambio global y la introducción de especies invasoras. Con testimonios de Anna Traveset del Instituto Mediterráneo de Estudios Avanzados. Bernardo Herradón nos ha hablado de nueva edición que está preparando del curso de divulgación "Los avances de la Química y su impacto en la sociedad", con ponentes muy destacados y temas muy interesantes. Esther García nos ha informado del proyecto PIM, una escuela de matemáticas para jóvenes dependiente del ICMAT, el Instituto de Ciencias Matemáticas, con el objetivo de fomentar vocaciones tempranas. Abrirá sus puertas en octubre aunque ya han comenzado las preinscripciones. Con testimonios de Eva Elduque y Moisés Herradón. Hemos reseñado los libros “Museo Nacional de Ciencias Naturales. Nuestra investigación al alcance de tu mano”, coordinado por Cristina Cánovas Fernández; "Embarazos y partos de las reinas de España. de Isabel Católica a doña Letizia", de Pedro Gargantilla y Berta Martín Cabrejas (La esfera de los libros); "Mira quien habla. Cosas que dicen los animales", de Francesca Buoninconti (Alianza editorial); "Orden, desorden y complejidad. Un camino hacia el origen de la vida", de Manuel J. Tello (Catarata); y “Una antropóloga en la Luna. Las historias más sorprendentes de la especie humana", de Noemí Villaverde (Oberón). Escuchar audio

Welcome to Episode 4 of the BioHackers Podcast! In this episode, David and Alex welcome Marc Birtwistle to the show. Together, they discuss mathematical modeling as a time machine for the cell, the lab of the future, great advice for careers in science, kinesthetic learning, and Marc's cool new company, Blotting Innovations.   Watch the Video Podcast on YouTube:  https://youtu.be/ATWPnCblx0M  Here is a list of topics: Welcome to Episode 4 (00:00)In Silico Science (01:01)Modeling Weather of the Cell (03:26)Welcome Marc to the Show (06:42)Don't Panic – Marc's Story I (08:54)Pivot into Biosciences (13:49)Lab of the Future (18:58)When You Stop Moving … You're Dead (24:54)Modeling is a Time Machine (27:01)Causality: Standing on the Shoulders of Giants (30:26)Modeling is an Aha Moment for Cell Biology (33:15)Models as Kinesthetic Learning Tools (40:45) Blotting Innovations – Marc's Story II (43:20)What is a BioHacker to You? (50:08)   Enjoy the Show! 

Artificial Intelligence in healthcare; academia, business and real-world. Sandeep Reddy is a medical informatician, health program evaluator, translational medicine specialist, academic and entrepreneur. Deakin University is a public university in Victoria, Australia. In this episode, Pete and Sandeep discuss AI in healthcare, specifically through the lens of academia, as well as business.  They also explore some practical applications of AI in healthcare and what the future might look like. Tune into this episode to learn how AI in healthcare compares to the real world versus academia. This episode will also cover topics like the future of AI in healthcare, the progression of AI over the years and the intrinsic value of artificial intelligence.  Check out the episode and full show notes here. To see the latest information, news, events and jobs on offer at Deakin University, visit their Talking HealthTech Directory here.  Loving the show?  Leave us a review, and share it with some friends, and let us know how we can improve by completing our podcast listener survey. Keen to take your healthtech to the next level? Become a THT+ Member for access to our online community forum, quarterly summits and more exclusive content.  For more information visit here.

Today, David is speaking with John Mizzi. John is the co-founder and CEO of Vero Technologies. He was previously the COO of Bond.One, a capital markets technology platform, focused on streamlining settlement and reconciliation functions for asset servicers (Corporate Trustees and Administrators) in the debt capital markets. As an entrepreneur-in-residence for Danish software company, cVation, he launched 2 fintech companies, Bond.One and IMTC. IMTC is a portfolio management software solution for investment managers. He is currently on the Board of Directors for the McCarton Foundation, a nonprofit organization that seeks to educate, empower, and provide exceptional treatment for children with autism. John attended the University of Michigan, graduating with a Bachelor of Arts degree in Economics. While in Ann Arbor, he co-founded InSilico, an education technology start-up focused on developing software solutions for children with Autism Spectrum Disorders. What You'll Learn: Managing Yourself and Employees  How a fintech product should look like to determine creditworthiness Process to raise a seed fund as a balance sheet lending business  FinTech milestones and ways to evaluate a FinTech company Go to market motion Channel Sales through banks  Level of Product Market-Fit 30/60/90 days plan after a $4M raise  Favorite Quote: “You do not do business with business, you do business with people” --  The Capital Stack All Things Tech Investing and Value Creation Early growth investor David Paul interviews the world's greatest ecosystem, learns how to start and scale your own business, and finds an edge in today's capital markets.  To connect with David, visit:   Twitter -https://twitter.com/davidpaulvc ( CLICK HERE) Substack -http://davidpaul.substack.com/ ( CLICK HERE) LinkedIn -http://linkedin.com/in/Davidpaulvc ( CLICK HERE) IG -https://www.instagram.com/davidpaulvc/ ( CLICK HERE)     DISCLAIMER: David Paul is the founder and general partner at DWP Capital.  All opinions expressed by David and podcast guests are solely their own opinions and do not reflect the opinions of DWP capital.  This podcast is for informational purposes only and should not be relied upon for decisions. David and guests may maintain positions in the securities discussed on this podcast.

Listen to a blog summary of a research paper chosen as the cover for Volume 14, Issue 6 of Aging (Aging-US), entitled, "Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine." _________________________________ What if drugs designed to treat conditions such as diabetes, osteoporosis and rheumatoid arthritis could at the same time provide patients with anti-aging benefits? On March 29, 2022, researchers—from Insilico Medicine, University of Chicago, George Mason University, University of Liverpool, and Buck Institute for Research on Aging—released a new study on the cover of Aging (Aging-US) Volume 14, Issue 6, about Insilico's next-generation artificial intelligence (AI)-powered discovery software, called the PandaOmics platform. Their trending research paper is entitled, “Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine.” Full blog - https://aging-us.org/2022/03/pandaomics-identifies-duel-targets-of-aging-and-age-related-diseases/ DOI - https://doi.org/10.18632/aging.203960 Corresponding author - Alex Zhavoronkov - alex@insilico.com Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.20396 Keywords - aging, artificial intelligence, deep learning, drug discovery, multi-omics, target identification About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at http://www.Aging-US.com​​ or connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/agingus​ LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

"In Silico” documentarian Noah Hutton discusses the project to simulate the human brain on a supercomputer. 

*The full podcast is available exclusively for Primordial Radio members via the website or via the Primordial app. Check it out here https://primordialradio.com/* Every week on the afternoon show, Dews plays an album in full, chosen by a member of the the PRFam, who then joins him on-air to have a chat about it. This podcast is the recording of those chats, minus the music. In ep62 of the podcast Dews is joined by Mark Edge to talk about car stereo theft, how someone goes from being into dance music to being a full-on rocker, and Pendulum's 2008 album "In Silico". 

No Agenda Episode 1403 - "In Silico" "In Silico" Executive Producers: Travis Carrico Jim Schneeberger Aaron Bojorquez David Schwanebeck Sir Davey Rob Campbell Alexander Nuttall Brian Lowrance Lee Rasor Nick Foster Sean O'Neal Associate Executive Producers: Sir Fromgar Sir Jeremy Chum-Phatti The Half Witted Tula Rainwater Jasmine McMahon Become a member of the 1404 Club, support the show here Boost us with with Podcasting 2.0 Certified apps: Podfriend - Breez - Sphinx - Podstation - Curiocaster - Fountain Knights & Dames Ryan Armstrong -> Sir Ryan Armstrong, Knight of the Silver Arrows Jim Schneeberger -> Sir Jimbabwe Art By: Roger Roundy End of Show Mixes: Sound guy Steve - Clip Custodian Neal Jones Engineering, Stream Management & Wizardry Mark van Dijk - Systems Master Ryan Bemrose - Program Director Back Office Aric Mackey Chapters: Dreb Scott Clip Custodian: Neal Jones NEW: and soon on Netflix: Animated No Agenda No Agenda Social Registration Sign Up for the newsletter No Agenda Peerage ShowNotes Archive of links and Assets (clips etc) 1403.noagendanotes.com New: Directory Archive of Shownotes (includes all audio and video assets used) archive.noagendanotes.com RSS Podcast Feed Full Summaries in PDF No Agenda Lite in opus format NoAgendaTorrents.com has an RSS feed or show torrents Last Modified 11/28/2021 14:32:02This page created with the FreedomController Last Modified 11/28/2021 14:32:02 by Freedom Controller  

David Silver, head of the Reinforcement Learning research group at DeepMind, is awarded the honorary ranking of "Ninth Dan" for AlphaGo. https://www.cnbc.com/2021/06/18/computer-scientists-ask-if-deepmind-can-ever-make-ai-human-like.html Insilico Medicine, an AI-based drug development and discovery platform, announced Tuesday Series C funding of $ 255 million. https://techcrunch.com/2021/06/22/a-i-drug-discovery-platform-insilico-medicine-announces-255-million-in-series-c-funding/?guccounter=1 XPRIZE, the world's leading provider of incentive competitions to solve the world's great challenges, and IBM Watson, IBM's AI technology for business, today announced the grand prize winner of the $ 5 million IBM Watson AI XPRIZE Challenge. " https://www.businesswire.com/news/home/20210623005848/en/Grand-Prize-Winner-Announced-in-5M-IBM-Watson-AI-XPRIZE-Competition NVIDIA announced Canvas, an app available in free beta that provides real-time painting tools for anyone with an NVIDIA RTX GPU. https://petapixel.com/2021/06/23/nvidia-new-canvas-app-uses-ai-to-turn-doodles-into-realistic-photos/ China's first female virtual student, developed by Tsinghua University, met with fans Thursday when she opened an account on China's Twitter-like Sina Weibo platform. https://www.globaltimes.cn/page/202106/1225392.shtml Visit www.integratedaisolutions.com

David Silver, Leiter der Forschungsgruppe Reinforcement Learning bei DeepMind, wird für AlphaGo mit dem Ehren-Rangliste "Neunter Dan" ausgezeichnet. https://www.cnbc.com/2021/06/18/computer-scientists-ask-if-deepmind-can-ever-make-ai-human-like.html Insilico Medicine, eine KI-basierte Plattform für die Entwicklung und Entdeckung von Medikamenten, kündigte am Dienstag eine Serie-C-Finanzierung in Höhe von 255 Millionen US-Dollar an. https://techcrunch.com/2021/06/22/a-i-drug-discovery-platform-insilico-medicine-announces-255-million-in-series-c-funding/?guccounter=1 XPRIZE, der weltweit führende Anbieter von Incentive-Wettbewerben zur Lösung der großen Herausforderungen der Menschheit, und IBM Watson, IBMs KI-Technologie für Unternehmen https://www.businesswire.com/new s/home/20210623005848/en/Grand-Prize-Winner-Announced-in-5M-IBM-Watson-AI-XPRIZE-Competition NVIDIA hat Canvas angekündigt, eine App, die als kostenlose Betaversion verfügbar ist und die Echtzeit-Malwerkzeuge für jeden mit einer NVIDIA RTX-GPU bietet. https://petapixel.com/2021/06/23/nvidia-new-canvas-app-uses-ai-to-turn-doodles-into-realistic-photos/ Chinas erste virtuelle Studentin, die von der Tsinghua-Universität entwickelt wurde, traf sich am Donnerstag mit Fans, als sie ein Konto auf Chinas Twitter-ähnlicher Sina Weibo-Plattform eröffnete. https://www.globaltimes.cn/page/202106/1225392.shtml Visit www.integratedaisolutions.com

Podcast jest dostępny także w formie newslettera: https://ainewsletter.integratedaisolutions.com/ David Silver, lider grupy badawczej ds. https://www.cnbc.com/2021/06/18/computer-scientists-ask-if-deepmind-can-ever-make-ai-human-like.html Insilico Medicine, oparta na sztucznej inteligencji platforma do opracowywania i odkrywania leków, ogłosiła we wtorek 255 milionów dolarów finansowania serii C. https://techcrunch.com/2021/06/22/a-i-drug-discovery-platform-insilico-medicine-announces-255-million-in-series-c-funding/?guccounter=1 XPRIZE, światowy lider w projektowaniu i prowadzeniu konkursów motywacyjnych mających na celu rozwiązywanie wielkich wyzwań ludzkości, oraz IBM Watson, technologia AI IBM dla biznesu, https://www.businesswire.com/news/home/20210623005848/en/Grand-Prize-Winner-Announced-in-5M-IBM-Watson-AI-XPRIZE-Competition NVIDIA ogłosiła Canvas, aplikację dostępną jako bezpłatną wersję beta, która, jak twierdzi, zapewnia narzędzia do malowania w czasie rzeczywistym każdemu, kto ma procesor graficzny NVIDIA RTX. https://petapixel.com/2021/06/23/nvidia-new-canvas-app-uses-ai-to-turn-doodles-into-realistic-photos/ Pierwsza chińska wirtualna studentka opracowana przez Uniwersytet Tsinghua spotkała się z fanami w czwartek, kiedy otworzyła konto na chińskiej platformie Sina Weibo podobnej do Twittera. https://www.globaltimes.cn/page/202106/1225392.shtml Odwiedź www.integratedaisolutions.com

On today's episode, we are making the full arc from the theoretical and borderline philosophical to the applied. Let's start with the theory: embodied intelligence posits that the body, or the physical form, plays an active and significant role in shaping an agent's mind and cognitive capacities. For example, human intelligence is not just the function of our brain, but a combination of our brain, our body, and the environment in which we exist. But when it comes to designing artificial intelligence (AI), a physical form and an environment are typically not part of the equation. It's a disembodied cognition. Our guests, Li Fei-Fei and Surya Ganguli of the Stanford Institute for Human-Centered AI, set out to develop what they call an “evolutionary playground” to explore the development of embodied intelligence in AI and its connection with the environment and with learning using in silico experiments. They discuss with a16z general partner Vijay Pande and host Lauren Richardson how they created a suite of virtual environments in which agents evolve through a process that mimics aspects of Darwinian evolution. These agents, called the unimal, or universal animal, start off as a central node, and with each generation can add or subtract limbs and change various properties of their physical forms, like how flexible their joints are. Just like in real evolution, different forms arose based on the particularities of the environment, but what is really exciting is what Fei-Fei, Surya, and colleagues discovered about the intelligence encoded in some of these forms, such as an increased ability to learn a novel task. Which brings us to the applied section of our discussion. These results provide new insights for how we think about designing robots capable of performing unique tasks, and for understanding the possible limitations of disembodied AI models, like GTP-3. The results are described in the pre-print "Embodied Intelligence via Learning and Evolution" posted on arXiv.org. And watch the unimal evolve here!

Boston's Transmit Security, which provides workforces risk management and passwordless identity solutions, has announced its Series A fundraise of $543 million, led by Insight Partners and General Atlantic. Additional investors include Cyberstarts, Geodesic, SYN Ventures, Vintage, and Artisanal Ventures. The company's pre-investment valuation was $2.2B, and it looks to work towards passwordless protection and identity risk management.Oyster, a software HR platform to address hiring problems in companies, announced its Series B fundraise of $50M, led by Stripes. The funding comes on the heels of its Series A funding, which it raised in February this year from San Mateo-based Emergence Capital. Chicago-based G2, a marketplace for business organizations to buy, research and manage their software, has attained unicorn status, raising $157M in a Series D funding round led by Permira and bags the unicorn tag. The round has valued the startup at $1.1 Billion.Insilico Medicine, an AI-based platform for medication discovery and research, has raised $255 million in a Series C round. It is a Hong Kong-based company founded in 2014 to discover novel drug targets for currently untreatable illnesses. In 2020, the firm identified a novel therapeutic target for idiopathic pulmonary fibrosis (IPF), a disease in which the tiny air sacs in the lungs scar and make breathing difficult.Splunk, a company that develops operational intelligence software, has secured $1 billion in funding from private equity firm Silver Lake. Silverlake's chair and managing partner, Ken Hao, will join the Splunk board of directors. The San Francisco-based company has introduced Splunk Security Cloud. Splunk also announced the completion of its acquisition of TruStar, a developer of security software.Mollie, a unicorn payments service provider in Europe, has announced its Series C fundraise of €665 million ($800 million) in a round led by Blackstone's growth equity investing business- Blackstone Growth (BXG). The company revealed that its valuation has touched €5.5 billion ($6.5 billion) post this round, making it one of the top five most valued privately held fintech companies in Europe.Merlyn Mind, an AI assistant for teachers, has received $29 million as initial funding from edtech investor Learn Capital and other undisclosed investors. With this announcement, Merlyn Mind has come out of stealth. It spent nearly three years developing its first version and, more recently, piloting the service in more than 50 classes across more than 20 schools.Zeller, a fintech company based in Melbourne that serves SMBs, has announced that it has raised AUD 50 million at an AUD 400 million valuation. The round was led by Spark Capital. Other participants include Square Peg, Apex Capital Partners, and Addition. The funds will be used to expand Zeller's research and engineering centre, including hiring 18 new engineering positions to help the company achieve its goal of being a fully regulated business bank.Memory.ai, a company that creates AI-based applications, has received $14 million in a round headed by Melesio and Sanden. The money will be utilized to develop new apps that will aid individuals in becoming more productive. Dewo and Glue are two applications that are in the works. Both of these apps will be available in the second half of this year.Toronto-based Joyride, offering solutions for micromobility operators, has announced that it has raised an oversubscribed amount, $3.7M as demand and popularity for e-scooters, bikes and mopeds go up. Its software platform enables businesses to launch, manage and scale their scooter-sharing and bike-sharing businesses all in one place. Joyride stated that the funding would enable it to take its micromobility software to the next level, to thousands of new markets

House prices have set records in the US and parts of Europe, and the artificial intelligence-based drug-discovery platform Insilico has raised more than $255m from investors. Plus, the deputy head of the FT's Lex column, Elaine Moore, explains why Instagram is struggling to stay relevant in today's social media landscape. House prices climb to record levels in US and Europehttps://www.ft.com/content/3082fe00-cdb7-4eb9-ab2d-2309b9848114AI drug discovery start-up Insilico raises more than $255m https://www.ft.com/content/704ced9a-dffd-49a1-a58f-46fc6dca0cd2Too many influencers, not enough eyeballs: will boredom kill Instagram? https://www.ft.com/content/9c00219a-229a-4b82-a7c3-63000b558053More than 5m people become millionaires despite pandemic https://www.ft.com/content/86b99144-ba71-441d-b297-ddcdc94ea7f2? See acast.com/privacy for privacy and opt-out information.

Eller er du en slave af tech? For ti år siden var mange af os optændt af forventningsfuld begejstring over mulighederne i kunstig intelligens, men udviklingen løb i en retning, hvor teknologien ikke kun hjælper os. Tværtimod bruges den til at udnytte os, spionere på sociale liv og kapitalisere på vores data. Den amerikanske techjournalist Kevin Roose fra New York Times er gået fra at være techoptimist til at være slave af sin iPhone og har nu skrevet en overlevelsesguide til mennesker i en automatiseret tidsalder; bogen "Futureproof" med ni gode råd til et balanceret liv med tech. Mød Kevin Roose i en debat med professor ved DTU Compute og robotekspert, Thomas Bolander, professor ved AAU, David Budtz Pedersen og lektor i neurorobotics ved DTU, Silvia Tolu. Vi var bragt sammen dokumentarfilmfestivalen CPH:DOX og Ingeniørforeningnen IDA på baggrund af dokumentarfilmen ‘In Silico,' der kan ses under CPH:DOX 2021. CPH:DOX 2021 løber fra 21. april til 12. maj. Læs mere om årets festival: https://cphdox.dk/da/

Bonus Episode: Interview with Noah Hutton, the director of the Gig economy based movie Lapsis.  Jesper and I had an incredible time talking with Noah The movie comes out on February 12th on all VOD platforms and in some theaters. Check local listings in your area. Movie Trailer Movie Website LAPSIS PRESS NOTES   Original sci-fi world with timely political themes: The film imagines a gig economy organized around a boom in quantum computing where predatory corporate forces threaten everyday workers tasked with the work needed to lay this new quantum infrastructure in rural areas. This work takes the form of laying cable through huge swaths of forests, connecting massive cubic transistors. The film portrays human laborers who are forced to work without basic protections and are often robbed of their routes by automated cabling robots. These themes are central to some of the political discourse surrounding the 2020 presidential campaign, raised by Andrew Yang and others, about the threat of automation and the issues faced by gig economy laborers around the world. They are also part of the growing awareness of the exploitation of workers subcontracted by big tech giants like Amazon, kept on timers and forced to sacrifice basic physical comforts in order to compete for their paychecks.   A twist on the sci-fi genre: Lapsis is a genre film, using sci-fi in similar ways to shows like Black Mirror. But instead of focusing on a glitzy, high tech, white-collar world like so many other sci-fi films and shows do, Lapsis is blue-collar sci-fi. It's a gritty story of the messy exploitative underbelly that tech companies often rely on to uphold their glossy facades.   Noah Hutton as first-time narrative director, bringing this world into focus: Noah wrote the original screenplay for Lapsis and rounded up a team of collaborators to make the world of the film come to life in upstate New York last summer. His vision included an army of automated robots, so he sought out a robotics lab at UPenn that had just the right solution for Lapsis. Working on a tight schedule with a diverse cast of over forty speaking parts, the weather gods cooperated and the film was shot in twenty-six days.   Noah Hutton as writer, director, composer, AND editor: Noah is a swiss army knife of talents. Directly after production wrapped, Noah started editing and scoring Lapsis. Noah has scored all his films, including his shorts, his previous two documentary features, and his upcoming documentary feature presented by Sandbox Films, In Silico.   A personal film: The ailing younger brother storyline is personal and autobiographical for Noah, and so the decision to cast his real-life brother, Babe Howard, as the younger brother character, Jamie, helped to ground the character building in authenticity and elevate the story's stakes.   The making of the film mirrored the message of the film: Director Noah Hutton distributed a production handbook (which is publicly available online and open-source), adapted from the lab handbook of CLEAR, a queer, feminist, radical ocean plastics lab in Newfoundland that Hutton previously made a short documentary about for The Atlantic. On the set of Lapsis, the production handbook enforced a set of policies meant to increase the equity amongst members of the crew. This included sharp policies on sexual harassment, no unpaid labor, and building in all full-time crew to the backend profit structure of the film.   Diverse cast: Cast featured over 40 speak

Perth's Pendulum are one of the biggest musical exports of the 2000s so far.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.31.363549v1?rss=1 Authors: L, L., V, V., Srihari, R., CN, P. Abstract: Introduction: Type 2 Diabetes Mellitus (T2DM) is a long-term metabolic disorder that primarily characterized by impaired insulin resistance to become hyperglycemia. People suffering from T2DM have a higher risk of developing various diseases but, on top of that, some diabetic drugs are also suspected of increasing the risk in some cases. Aldose reductase is a key target enzyme to catalyze the reduction of glucose to sorbitol and does not readily diffuse across cell membranes and cause retinopathy and neuropathy. The aldolase reductase inhibitors prevent the conversion of glucose to sorbitol and may have the capacity of preventing and / or treating several diabetic complications. It will be expected to be twofold in the subsequent decade due to intensification in the senile population with the number of people affected, thus adding to the liability on medical providers in poor developed countries using herbal medicine to control the diabetes. In recent investigation, the antidiabetic property of phytochemicals extracted from leafs of Abutilon indicum (L.) is elucidated using animal models. Materials and Methods: In the current study using aldose reductase enzyme assay inhibitor of Rat lens Aldose reductase were treated with A. indicum methanolic leaf extract at different concentrations (6.25, 12.5, 25, 50, 100, and 200microgram/mL). Copper sulphate was used as reference drug and docking studies to predict the screen the best aldose reductase inhibitor. Results and Discussion: The crude extract exhibited cytotoxicity against rat lens aldose reductase (IC50 = 135.8 {+/-} 956;g/L vs ref 13.60 {+/-} 956;g/L) using In Vitro. The docking is performed with 11 compounds shows Ertugliflozin, 9H-Cycloisolongifolene, 8-oxo and 7-hydroxycadalene showed a good binding interaction with aldose reductase. Conclusion: We are concluding that the invitro and in silico analysis helps researchers to utilize these compound for aldose reductase inhibitors and further can be used for clinical applications. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.30.362764v1?rss=1 Authors: Dasgupta, R., Pradhan, A. K., Ghosh, S. Abstract: Mycobacterium are a genus of Actinobacteria known to be responsible for several deadly diseases in both humans and animals, including tuberculosis. Luciferase is the primary protein in Mycobacteria that plays a role in bioluminescence. It also plays a role in some bacteria of being a source of energy transference, such as in the case of lumazine proteins. Although studies have been conducted in different luciferase in bacteria, there has been hardly any structural studies on luciferase expressed in Mycobacterium sp. EPa45. Therefore, in this paper we have studied luciferase expressed in Mycobacterium sp. EPa45 by insilico analysis of its structure from its protein sequence. We report the observed differences within luciferase reported from other strains of mycobacterium and pathogenic and non-pathogenic forms of bacteria in terms of their (i) physiochemical characteristics, (ii) protein structure, (iii) multiple sequence alignment and (iv) phylogenetic relationships. We report for the first time the relation of this specific strain of Luciferase in mycobacterium and bacterium at large. Highlights: 1. Mycobacterium sp. EPa45 shows similar characteristics to pathogenic mycobacterium 2. Analysis of Luciferase sequence and protein qualities provides insight to pathogenicity 3. The deadly nature of infectious mycobacterium, especially with luciferase sequences similar to Mycobacterium sp. EPa45, is analyzed Copy rights belong to original authors. Visit the link for more info

Flood is a Bitcoin trader and we discuss the changing Bitcoin regime, trading an explosive trend, transitioning from Defi to Bitcoin, trading strategy, investing vs trading, his trading suite (InSilico), and market outlook. Thank you for listening to the show. If you could please leave me a rating on iTunes, I would really appreciate it. Tweet me your thoughts about the episode! Show sponsors: •Matcha: Find the best prices across crypto exchange networks: https://matcha.xyz/ •Fun, Fast, and Fair gaming with a dedicated Bitcoin company: CoinGaming •Bybit: Trade Bitcoin, ETH, EOS, and XRP derivatives and get a deposit bonus with the show link: Bybit_Deposit_Bonus

This “king of bitters” (so-called because of its flavor) has been used for centuries in Asia to treat gut and upper respiratory infections, fever, herpes, sore throat, and other chronic and infectious disease conditions. However, modern research is demonstrating Andrographis paniculata’s benefits include aiding with joint conditions such as arthritis. ParActin®: A Potent Form of Andrographis Paniculata for Pain Support & More The medicinal herb Andrographis paniculata has been traditionally used for its powerful anti-inflammatory properties and its ability to boost immune system activity. This “king of bitters” (so-called because of its flavor) has been used for centuries in Asia to treat gut and upper respiratory infections, fever, herpes, sore throat, and other chronic and infectious disease conditions [1]. However, modern research is demonstrating Andrographis paniculata’s benefits include aiding with joint conditions such as arthritis and it may even have anti-cancer benefits. Andrographis Goes by Many Names Andrographis is cultivated in many tropical Asian countries including India, China, Malaysia, Indonesia, and Sri Lanka, as well as in the West Indies, Brazil, parts of Africa, and Central America. Known as “chuan-xin-lian” in China, “kalmegh” in India, “senshinren” in Japan, “hempedu bumi” in Malaysia, “fah talai” in Thailand, and “green chiretta” in the Scandinavian countries, Andrographis is listed in the Indian Pharmacopoeia (a publication that lists standards for all drugs that are manufactured, sold, and consumed in India) and in a couple of dozen Ayurvedic formulas [2]. In traditional Chinese medicine (TCM), Andrographis is believed to rid the body of heat (e.g., fevers) and to dispel toxins [3]. Phytochemistry of Andrographis Paniculata Andrographis leaves are mainly responsible for its biological actions. They contain many bioactive compounds, including diterpene lactones – especially Andrographolide, the main bioactive ingredient that imparts the typical bitter taste. Andrographolide is an antioxidant that has been shown to be responsible for the herb’s anti-viral and anti-bacterial properties. Andrographolide is also reported in scientific literature to reduce blood clot formation, help protect the liver, have anti-cancer properties, and manage inflammation within safe levels [4]. What Is ParActin®? ParActin® is a patented extract of A. Paniculata, standardized to a fixed concentration of Andrographolide and other related compounds including 14-deoxyandrographolides and neoandrographolides [5]. Preliminary research shows that ParActin® promotes a healthy inflammatory response by blocking a powerful chemical known as NF-kappa B, which is known to be a key regulator of the inflammatory response system. As a result, ParActin® helps support a healthy and appropriate inflammatory response by reducing the levels of pro-inflammatory compounds that trigger the familiar pain and redness associated with inflammation. The safety and efficacy of ParActin® has been assessed in more than 30 studies, including laboratory experiments on cultured cells and animal models – and even a human clinical trial. Let’s take a closer look at some of these studies and what they tell us about Andrographis and ParActin®. Inflammation Is Linked to Many Disease Conditions Long-term, chronic inflammation that occurs when the immune system goes into overdrive may lie at the root of many otherwise unrelated diseases, including: asthma inflammatory bowel disease (IBD) rheumatoid arthritis (RA) autoimmune diseases depression cancer Alzheimer’s disease Inflammation – which manifests as swelling, redness, heat, and pain – is a normal response of our immune system and our body’s way of defending us from infections and disease. However, if it’s not managed properly, inflammation can harm the body. Chronic inflammation is the result of an overactive immune system that is constantly turned on – or cannot be turned off – so that it attacks parts of the very body it is supposed to protect. So-called oxygenated chemical species – including free radicals, oxygen ions, and peroxides – are continuously made in our body’s cells in response to UV radiation and as byproducts of ongoing metabolic activity. They are highly reactive and dangerous, because they can attack cellular DNA and proteins, damaging them. When oxygenated chemical species are generated in excess, they can overwhelm cellular defense systems, leading to a condition known as oxidative stress along with high levels of inflammation – which, as we discussed earlier, is known to contribute to the development of many diseases. Andrographolide, the best-known bioactive ingredient in Andrographis, has been shown to directly inactivate free radicals. It also protects mitochondria, blocks pro-oxidant enzymes, and activates other antioxidant enzymes in the body [6]. Andrographis Boosts the Immune System Andrographolide has been shown to enhance the immune system. For example, it boosts production of white blood cells known as lymphocytes, which scavenge and destroy bacteria and other foreign matter. It also triggers the release of signaling proteins known as interferons, along with enhancing activity of the lymphatic system [7]. Interferons are made and released by our body’s cells when they get infected with viruses, causing nearby cells to strengthen their anti-viral defenses. Interferons are potent antiviral agents that stop viruses from multiplying. The lymphatic system is another circulatory system in our body that carries a fluid known as lymph, which removes the waste products of cellular metabolism. The lymphatic system also transports invading bacteria and viruses to lymph nodes where the white blood cells (lymphocytes) destroy them. Andrographis has been shown to trigger our immune system in two ways: Antigen-specific response – specific proteins known as antibodies are made to counteract invading bacteria and viruses. Nonspecific immune response – immune cells known as macrophages are produced, which scavenge and destroy invaders. Andrographis activates both responses, meaning it is very effective against a variety of infectious and cancer-causing agents [8]. Benefits for Upper Respiratory Tract Infections & Cough Andrographis has been used for many hundreds of years in traditional medicinal systems to treat upper respiratory infections. Modern research supports this. For example, a 2004 meta-analysis of the results of seven double-blind, controlled trials (with a total of 896 participants) showed that Andrographis offers significant relief from the symptoms of upper respiratory tract infections and may even prevent them from taking hold in the first place. [Note: A meta-analysis is a quantitative epidemiological study used to systematically assess the results of previous research – typically randomized, controlled clinical trials – to derive overall conclusions about that body of research.] All the participants in these seven clinical trials reported reduced fever, runny nose, cough, and sore throat on taking Andrographis relative to control patients. Side effects were described as “generally mild and infrequent” [9]. Similarly, another meta-analysis published in 2015 reviewed six randomized controlled clinical trials, which assessed the effects of Andrographis in the treatment of cough. Combined, these six studies compared 333 patients who took various Andrographis preparations relative to 348 patients in control groups. All of these studies showed that Andrographis preparations reduced cough severity [10]. Andrographis Heals the Gut As mentioned above, Andrographis has long been used in traditional medicinal systems such as Ayurveda and traditional Chinese medicine (TCM) for treating gut infections. In a 2013 study published in the American Journal of Gastroenterology, 224 patients with mild to moderate ulcerative colitis were either given 1200 or 1800 milligrams of Andrographis for 8 weeks. Ulcerative colitis is an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the gut, affecting the innermost lining of the large intestine (colon) and rectum. A colonoscopy was performed before the study started and after it ended. Stool frequency and the presence of blood in the stool were also assessed every two weeks. At the end of the study, 60% of patients who received 1800 mg of Andrographis – relative to 40% of patients in the control group – showed clinical symptoms of healing. Not only that, 50% of the patients who received the 1800 mg of Andrographis also showed mucosal healing, relative to 33% in the control group [11]. Andrographis & Joint Pain from Arthritis Arthritis affects more than 70 million Americans, leading to inflammation, pain, and stiffness in the joints and connective tissues. Over time, cartilage breaks down, bones erode, and joints become misshapen [12]. Our modern understanding is that rheumatoid arthritis (RA) happens because of the uncontrolled inflammation that is typical of an autoimmune disease. In such situations, the body’s defense mechanism malfunctions and attacks its own tissues (e.g., healthy joints) for a prolonged period of time. An immune-signaling protein known as cachexin or tumor necrosis factor-alpha is one of the key drivers of inflammation. Andrographolide has been shown to lower levels of cachexin. ParActin® and Mild Knee Osteoarthritis In a randomized, double-blind, placebo-controlled study the efficacy of ParActin® (300 and 600 mg daily) was assessed on pain reduction in 103 patients with mild to moderate knee osteoarthritis [13]. Patients treated with ParActin® showed a significant reduction in pain relative to the control group. Stiffness, physical function, and fatigue all showed a significant improvement with ParActin® treatment. At the end of the study, quality of life and Functional Assessment of Chronic Illness Therapy (FACIT) scores were significantly better in the ParActin®-treated groups compared to the control group. ParActin® and Rheumatoid Arthritis Similarly, in a randomized, double-blind and placebo-controlled study published in the journal Clinical Rheumatology in 2009, 60 individuals with compromised joints were given 100 mg of ParActin® or placebo in conjunction with methotrexate, three times a day for 14 weeks [14]. Methotrexate is proven to improve RA symptoms, but long-term use can cause serious infection and liver damage. In this study, ParActin® was effective in reducing the number and total grade of swollen joints, the number and total grade of tender joints, as well as improving scores on HAQ-52 (52-week Health Assessment Questionnaire), and SF-36 (36-item short form survey) health questionnaires. ParActin® treatment was associated with a reduction of various proteins, including enzymes, associated with cartilage damage. Currently, a human clinical trial testing the safety and efficacy of ParActin® in patients with mild to moderate osteoarthritis is ongoing. In other laboratory experiments, ParActin® and Andrographolide have also been shown to support bone [15]12, cartilage [16]13, and muscle [17]14 health and recovery. Can Andrographis Help Fight Cancer? Cancer results when our body’s cells grow uncontrollably. When cells develop normally, they become more and more specialized in their function at each stage of development. For example, immature pancreatic cells that will eventually go on to make insulin will develop the cellular machinery to do so as they become mature pancreatic cells. When cancer happens, it interferes with normal cellular development and cells do not mature. In fact, cancer cells resemble immature body cells – and the more they resemble immature cells, the more likely it is that they will spread to other locations – known as metastasis, often with fatal consequences. So, it logically follows that if cancer cells can be made to forcibly undergo maturation or differentiation, they will lose the ability to grow uncontrollably. Indeed, in one laboratory study in mice, researchers showed that Andrographis could induce differentiation in leukemia cells [18]. [Note: Leukemia is a cancer of the white blood cells, which are part of the immune system.] Andrographis can induce differentiation in laboratory conditions – but does this mean it can fight cancer? Indeed, it can – at least under laboratory conditions. A systematic review of no less than 139 pre-clinical and clinical studies shows that Andrographolide has anticancer effects on almost all types of cell lines in laboratory experiments [19]. Specifically, a 2019 study showed that Andrographolide prevented human colon cancer cells in culture from multiplying by inducing a process known as “programmed cell death” or apoptosis. Further, Andrographolide also displayed a combinatorial effect with chemotherapeutic anticancer drugs in these cells under laboratory conditions [20]. Similarly, the results of a 2019 study showed that a hot water extract of Andrographis could stimulate the production of specific components of the immune system and restore others to a more normal state. Furthermore, the Andrographis extract prevented tumor growth and metastasis in these mice, once again by inducing apoptosis, but without causing severe body weight loss as many anticancer chemotherapy drugs tend to do. Blood tests detected multiple bioactive Andrographis-derived diterpene compounds, suggesting that more than one might have contributed towards the beneficial effects seen in this study [21]. Andrographis extracts – especially bioactive lactone and diterpene compounds such as Andrographolide in them – have been shown to be very potent in suppressing the growth of various types of cancer cells in laboratory studies. In particular, Andrographolide has been shown to block the growth of human breast, prostate, and hepatoma tumors. It has even successfully been used in cancer chemotherapy [22]. Can Andrographis Help Prevent Alzheimer’s Disease? As a closing note, Andrographis is even showing promise in helping to combat Alzheimer’s disease. In a 2019 study published in the journal Plants – Basel, researchers reported that three compounds isolated from Andrographis may help stop the formation of structures known as beta-amyloid plaques, which underlie neurotoxicity and dementia, including Alzheimer’s disease [23]. As noted by the researchers “Andrographis paniculata and Spilanthes paniculata are used extensively as medicinal herbs for the treatment of various ailments, and are reported to have neuroprotective properties.”   Deeper Dive Resources   Organixx’s Turmeric T3D https://shop.organixx.com/a/secure/checkout/OobbS9ROAoETfnAGmGDF?ch-tn-box=first-box&gl=5d8908c502e26b5f0c38083c   Organixx Save & Subscribe Program https://organixx.com/subscribe-and-save/?gl=5eeaa19c8ebf588562f75d8f [1] Andrographis: In-depth review [2] Andrographolide, a Natural Antioxidant: An Update [3] Andrographis: In-depth review [4] Andrographolide, a Natural Antioxidant: An Update [5] ParActin® [6] Andrographolide, a Natural Antioxidant: An Update [7] Andrographis: In-depth review [8] Immunostimulant agents from Andrographis paniculata. [9] Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. [10] Herbal Medicine for Cough: A Systematic Review and Meta-Analysis. [11] Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. [12] HP Ingredients: ParActin Joint Health. [13] A double-blind, randomized, placebo-controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis. [14] Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. [15] Assessment of the Efficacy of ParActin® in Subjects With Mild to Moderate Osteoarthritis (ParActin) [16] ParActin: Healthy Bone Support [17] ParActin: Healthy Cartilage Support [18] ParActin: Muscle Health and Recovery [19] Cell differentiation-inducing diterpenes from Andrographis paniculata Nees. [20] Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer. [21] Antiproliferative and Apoptotic Properties of Andrographolide Against Human Colon Cancer DLD1 Cell Line [22] Multiple modulatory activities of Andrographis paniculata on immune responses and xenograft growth in esophageal cancer preclinical models. [23] Andrographolide and analogues in cancer prevention. [24] Multi-Target β-Protease Inhibitors from Andrographis paniculata: In Silico and In Vitro Studies. Study builds scientific support for HP Ingredients’ ParActin for joint health https://www.nutraingredients-usa.com/Article/2019/05/08/Study-builds-scientific-support-for-HP-Ingredients-ParActin-for-joint-health   A double-blind, randomized, placebo-controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis. https://www.ncbi.nlm.nih.gov/pubmed/30968986     Subscribe to Empowering You Organically  Never miss an episode!    APPLE PODCASTS                 SPOTIFY                 GOOGLE PODCASTS      

This “king of bitters” (so-called because of its flavor) has been used for centuries in Asia to treat gut and upper respiratory infections, fever, herpes, sore throat, and other chronic and infectious disease conditions. However, modern research is demonstrating Andrographis paniculata’s benefits include aiding with joint conditions such as arthritis. ParActin®: A Potent Form of Andrographis Paniculata for Pain Support & More The medicinal herb Andrographis paniculata has been traditionally used for its powerful anti-inflammatory properties and its ability to boost immune system activity. This “king of bitters” (so-called because of its flavor) has been used for centuries in Asia to treat gut and upper respiratory infections, fever, herpes, sore throat, and other chronic and infectious disease conditions [1]. However, modern research is demonstrating Andrographis paniculata’s benefits include aiding with joint conditions such as arthritis and it may even have anti-cancer benefits. Andrographis Goes by Many Names Andrographis is cultivated in many tropical Asian countries including India, China, Malaysia, Indonesia, and Sri Lanka, as well as in the West Indies, Brazil, parts of Africa, and Central America. Known as “chuan-xin-lian” in China, “kalmegh” in India, “senshinren” in Japan, “hempedu bumi” in Malaysia, “fah talai” in Thailand, and “green chiretta” in the Scandinavian countries, Andrographis is listed in the Indian Pharmacopoeia (a publication that lists standards for all drugs that are manufactured, sold, and consumed in India) and in a couple of dozen Ayurvedic formulas [2]. In traditional Chinese medicine (TCM), Andrographis is believed to rid the body of heat (e.g., fevers) and to dispel toxins [3]. Phytochemistry of Andrographis Paniculata Andrographis leaves are mainly responsible for its biological actions. They contain many bioactive compounds, including diterpene lactones – especially Andrographolide, the main bioactive ingredient that imparts the typical bitter taste. Andrographolide is an antioxidant that has been shown to be responsible for the herb’s anti-viral and anti-bacterial properties. Andrographolide is also reported in scientific literature to reduce blood clot formation, help protect the liver, have anti-cancer properties, and manage inflammation within safe levels [4]. What Is ParActin®? ParActin® is a patented extract of A. Paniculata, standardized to a fixed concentration of Andrographolide and other related compounds including 14-deoxyandrographolides and neoandrographolides [5]. Preliminary research shows that ParActin® promotes a healthy inflammatory response by blocking a powerful chemical known as NF-kappa B, which is known to be a key regulator of the inflammatory response system. As a result, ParActin® helps support a healthy and appropriate inflammatory response by reducing the levels of pro-inflammatory compounds that trigger the familiar pain and redness associated with inflammation. The safety and efficacy of ParActin® has been assessed in more than 30 studies, including laboratory experiments on cultured cells and animal models – and even a human clinical trial. Let’s take a closer look at some of these studies and what they tell us about Andrographis and ParActin®. Inflammation Is Linked to Many Disease Conditions Long-term, chronic inflammation that occurs when the immune system goes into overdrive may lie at the root of many otherwise unrelated diseases, including: asthma inflammatory bowel disease (IBD) rheumatoid arthritis (RA) autoimmune diseases depression cancer Alzheimer’s disease Inflammation – which manifests as swelling, redness, heat, and pain – is a normal response of our immune system and our body’s way of defending us from infections and disease. However, if it’s not managed properly, inflammation can harm the body. Chronic inflammation is the result of an overactive immune system that is constantly turned on – or cannot be turned off – so that it attacks parts of the very body it is supposed to protect. So-called oxygenated chemical species – including free radicals, oxygen ions, and peroxides – are continuously made in our body’s cells in response to UV radiation and as byproducts of ongoing metabolic activity. They are highly reactive and dangerous, because they can attack cellular DNA and proteins, damaging them. When oxygenated chemical species are generated in excess, they can overwhelm cellular defense systems, leading to a condition known as oxidative stress along with high levels of inflammation – which, as we discussed earlier, is known to contribute to the development of many diseases. Andrographolide, the best-known bioactive ingredient in Andrographis, has been shown to directly inactivate free radicals. It also protects mitochondria, blocks pro-oxidant enzymes, and activates other antioxidant enzymes in the body [6]. Andrographis Boosts the Immune System Andrographolide has been shown to enhance the immune system. For example, it boosts production of white blood cells known as lymphocytes, which scavenge and destroy bacteria and other foreign matter. It also triggers the release of signaling proteins known as interferons, along with enhancing activity of the lymphatic system [7]. Interferons are made and released by our body’s cells when they get infected with viruses, causing nearby cells to strengthen their anti-viral defenses. Interferons are potent antiviral agents that stop viruses from multiplying. The lymphatic system is another circulatory system in our body that carries a fluid known as lymph, which removes the waste products of cellular metabolism. The lymphatic system also transports invading bacteria and viruses to lymph nodes where the white blood cells (lymphocytes) destroy them. Andrographis has been shown to trigger our immune system in two ways: Antigen-specific response – specific proteins known as antibodies are made to counteract invading bacteria and viruses. Nonspecific immune response – immune cells known as macrophages are produced, which scavenge and destroy invaders. Andrographis activates both responses, meaning it is very effective against a variety of infectious and cancer-causing agents [8]. Benefits for Upper Respiratory Tract Infections & Cough Andrographis has been used for many hundreds of years in traditional medicinal systems to treat upper respiratory infections. Modern research supports this. For example, a 2004 meta-analysis of the results of seven double-blind, controlled trials (with a total of 896 participants) showed that Andrographis offers significant relief from the symptoms of upper respiratory tract infections and may even prevent them from taking hold in the first place. [Note: A meta-analysis is a quantitative epidemiological study used to systematically assess the results of previous research – typically randomized, controlled clinical trials – to derive overall conclusions about that body of research.] All the participants in these seven clinical trials reported reduced fever, runny nose, cough, and sore throat on taking Andrographis relative to control patients. Side effects were described as “generally mild and infrequent” [9]. Similarly, another meta-analysis published in 2015 reviewed six randomized controlled clinical trials, which assessed the effects of Andrographis in the treatment of cough. Combined, these six studies compared 333 patients who took various Andrographis preparations relative to 348 patients in control groups. All of these studies showed that Andrographis preparations reduced cough severity [10]. Andrographis Heals the Gut As mentioned above, Andrographis has long been used in traditional medicinal systems such as Ayurveda and traditional Chinese medicine (TCM) for treating gut infections. In a 2013 study published in the American Journal of Gastroenterology, 224 patients with mild to moderate ulcerative colitis were either given 1200 or 1800 milligrams of Andrographis for 8 weeks. Ulcerative colitis is an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the gut, affecting the innermost lining of the large intestine (colon) and rectum. A colonoscopy was performed before the study started and after it ended. Stool frequency and the presence of blood in the stool were also assessed every two weeks. At the end of the study, 60% of patients who received 1800 mg of Andrographis – relative to 40% of patients in the control group – showed clinical symptoms of healing. Not only that, 50% of the patients who received the 1800 mg of Andrographis also showed mucosal healing, relative to 33% in the control group [11]. Andrographis & Joint Pain from Arthritis Arthritis affects more than 70 million Americans, leading to inflammation, pain, and stiffness in the joints and connective tissues. Over time, cartilage breaks down, bones erode, and joints become misshapen [12]. Our modern understanding is that rheumatoid arthritis (RA) happens because of the uncontrolled inflammation that is typical of an autoimmune disease. In such situations, the body’s defense mechanism malfunctions and attacks its own tissues (e.g., healthy joints) for a prolonged period of time. An immune-signaling protein known as cachexin or tumor necrosis factor-alpha is one of the key drivers of inflammation. Andrographolide has been shown to lower levels of cachexin. ParActin® and Mild Knee Osteoarthritis In a randomized, double-blind, placebo-controlled study the efficacy of ParActin® (300 and 600 mg daily) was assessed on pain reduction in 103 patients with mild to moderate knee osteoarthritis [13]. Patients treated with ParActin® showed a significant reduction in pain relative to the control group. Stiffness, physical function, and fatigue all showed a significant improvement with ParActin® treatment. At the end of the study, quality of life and Functional Assessment of Chronic Illness Therapy (FACIT) scores were significantly better in the ParActin®-treated groups compared to the control group. ParActin® and Rheumatoid Arthritis Similarly, in a randomized, double-blind and placebo-controlled study published in the journal Clinical Rheumatology in 2009, 60 individuals with compromised joints were given 100 mg of ParActin® or placebo in conjunction with methotrexate, three times a day for 14 weeks [14]. Methotrexate is proven to improve RA symptoms, but long-term use can cause serious infection and liver damage. In this study, ParActin® was effective in reducing the number and total grade of swollen joints, the number and total grade of tender joints, as well as improving scores on HAQ-52 (52-week Health Assessment Questionnaire), and SF-36 (36-item short form survey) health questionnaires. ParActin® treatment was associated with a reduction of various proteins, including enzymes, associated with cartilage damage. Currently, a human clinical trial testing the safety and efficacy of ParActin® in patients with mild to moderate osteoarthritis is ongoing. In other laboratory experiments, ParActin® and Andrographolide have also been shown to support bone [15]12, cartilage [16]13, and muscle [17]14 health and recovery. Can Andrographis Help Fight Cancer? Cancer results when our body’s cells grow uncontrollably. When cells develop normally, they become more and more specialized in their function at each stage of development. For example, immature pancreatic cells that will eventually go on to make insulin will develop the cellular machinery to do so as they become mature pancreatic cells. When cancer happens, it interferes with normal cellular development and cells do not mature. In fact, cancer cells resemble immature body cells – and the more they resemble immature cells, the more likely it is that they will spread to other locations – known as metastasis, often with fatal consequences. So, it logically follows that if cancer cells can be made to forcibly undergo maturation or differentiation, they will lose the ability to grow uncontrollably. Indeed, in one laboratory study in mice, researchers showed that Andrographis could induce differentiation in leukemia cells [18]. [Note: Leukemia is a cancer of the white blood cells, which are part of the immune system.] Andrographis can induce differentiation in laboratory conditions – but does this mean it can fight cancer? Indeed, it can – at least under laboratory conditions. A systematic review of no less than 139 pre-clinical and clinical studies shows that Andrographolide has anticancer effects on almost all types of cell lines in laboratory experiments [19]. Specifically, a 2019 study showed that Andrographolide prevented human colon cancer cells in culture from multiplying by inducing a process known as “programmed cell death” or apoptosis. Further, Andrographolide also displayed a combinatorial effect with chemotherapeutic anticancer drugs in these cells under laboratory conditions [20]. Similarly, the results of a 2019 study showed that a hot water extract of Andrographis could stimulate the production of specific components of the immune system and restore others to a more normal state. Furthermore, the Andrographis extract prevented tumor growth and metastasis in these mice, once again by inducing apoptosis, but without causing severe body weight loss as many anticancer chemotherapy drugs tend to do. Blood tests detected multiple bioactive Andrographis-derived diterpene compounds, suggesting that more than one might have contributed towards the beneficial effects seen in this study [21]. Andrographis extracts – especially bioactive lactone and diterpene compounds such as Andrographolide in them – have been shown to be very potent in suppressing the growth of various types of cancer cells in laboratory studies. In particular, Andrographolide has been shown to block the growth of human breast, prostate, and hepatoma tumors. It has even successfully been used in cancer chemotherapy [22]. Can Andrographis Help Prevent Alzheimer’s Disease? As a closing note, Andrographis is even showing promise in helping to combat Alzheimer’s disease. In a 2019 study published in the journal Plants – Basel, researchers reported that three compounds isolated from Andrographis may help stop the formation of structures known as beta-amyloid plaques, which underlie neurotoxicity and dementia, including Alzheimer’s disease [23]. As noted by the researchers “Andrographis paniculata and Spilanthes paniculata are used extensively as medicinal herbs for the treatment of various ailments, and are reported to have neuroprotective properties.”   Deeper Dive Resources   Organixx’s Turmeric T3D https://shop.organixx.com/a/secure/checkout/OobbS9ROAoETfnAGmGDF?ch-tn-box=first-box&gl=5d8908c502e26b5f0c38083c   Organixx Save & Subscribe Program https://organixx.com/subscribe-and-save/?gl=5eeaa19c8ebf588562f75d8f [1] Andrographis: In-depth review [2] Andrographolide, a Natural Antioxidant: An Update [3] Andrographis: In-depth review [4] Andrographolide, a Natural Antioxidant: An Update [5] ParActin® [6] Andrographolide, a Natural Antioxidant: An Update [7] Andrographis: In-depth review [8] Immunostimulant agents from Andrographis paniculata. [9] Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. [10] Herbal Medicine for Cough: A Systematic Review and Meta-Analysis. [11] Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. [12] HP Ingredients: ParActin Joint Health. [13] A double-blind, randomized, placebo-controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis. [14] Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. [15] Assessment of the Efficacy of ParActin® in Subjects With Mild to Moderate Osteoarthritis (ParActin) [16] ParActin: Healthy Bone Support [17] ParActin: Healthy Cartilage Support [18] ParActin: Muscle Health and Recovery [19] Cell differentiation-inducing diterpenes from Andrographis paniculata Nees. [20] Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer. [21] Antiproliferative and Apoptotic Properties of Andrographolide Against Human Colon Cancer DLD1 Cell Line [22] Multiple modulatory activities of Andrographis paniculata on immune responses and xenograft growth in esophageal cancer preclinical models. [23] Andrographolide and analogues in cancer prevention. [24] Multi-Target β-Protease Inhibitors from Andrographis paniculata: In Silico and In Vitro Studies. Study builds scientific support for HP Ingredients’ ParActin for joint health https://www.nutraingredients-usa.com/Article/2019/05/08/Study-builds-scientific-support-for-HP-Ingredients-ParActin-for-joint-health   A double-blind, randomized, placebo-controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis. https://www.ncbi.nlm.nih.gov/pubmed/30968986     Subscribe to Empowering You Organically  Never miss an episode!    APPLE PODCASTS                 SPOTIFY                 GOOGLE PODCASTS      

Most of us would define longevity in terms of the length of our lives. But what if there’s more to it than that? What if quality matters as much as quantity? What if we could extend our healthiest, most productive years?Alex Zhavoronkov is the Founder and CEO of Insilico Medicine, a venture-backed company that seeks to extend healthy longevity through innovative AI solutions for drug discovery and aging research. Insilico has R&D labs in Belgium, the UK, Korea, Russia, Hong Kong, the US and Taiwan, and in 2017, the company was named one of NVIDIA’s Top 5 AI companies in its potential for social impact.   On the inaugural episode of HLTH Matters, Alex joins Dr. Kuku and Dr. Shlain to discuss his work in the field of longevity biotechnology, describing his particular focus on extending our most productive years as opposed to the end of life. He introduces us to the new science around aging clocks and weighs in on the possibilities of using their data to reverse age-associated pathologies. Listen in for Alex’s insight around the potential for AI to influence our political systems and learn how a sole focus on rejuvenation rate would support global economic growth.Topics CoveredAlex’s transition from information technology to biopharmaThe intersection of technology and the human elementThe concept of quality-adjusted life years or QALYsAlex’s focus on extending productive years vs. end of lifeHow Alex sees longevity as more than just living longerThe science around aging clocks and their notable accuracyDeveloping actionable interventions from aging clock dataHow economic forces influence which diseases we researchEmbracing MMA principles as an approach to drug discoveryAlex’s work with triple-negative breast cancer moleculesAlex’s insight into how AI might influence political systemsThe parallels between gain of function and economic growthHow Peter Diamandis’ work gives Alex cause for optimism Connect with Alex ZhavoronkovInsilico MedicineAlex on LinkedIn Connect with Dr. Gulati, Dr. Shlain & Dr. KukuHLTH ConferenceDr. Shlain on LinkedInDr. Shlain on TwitterDr. Kuku on LinkedInDr. Kuku on TwitterResourcesDeep Medicine: How Artificial Intelligence Can Make Healthcare Human Again by Eric TopolThe Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy by Alex ZhavoronkovSteven Horvath’s Aging Clock ResearchInsilico’s Partnership with CTFHAbundance: The Future is Better Than You Think by Peter H. Diamandis and Steven KotlerExponential Medicine

Alex Zhavoronkov is a particularly high level human being, originally working in the field of computer science, Alex had a realization that contributing to aging and aging research would be the biggest contribution he could make for humanity. Utilizing his expertise in computer science and artificial intelligence, he began using these skills to enter the world of longevity in a significant way. Artificial intelligence will play a massive role in drug and biomarker discovery going forward and Alex's company, Insilico Medicine is leading the charge in a serious way.It was an absolute honor to speak with Alex Zhavoronkov as he explained in simple terms just how exciting Insilico's tech is. How it works, all the different projects they are involved in, and just how much of a financial behemoth Insilico has the potential to be. (Keep an eye out for their IPO in the next few years)-James Ruhle, SimpleBioTechPodcast.comStay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTechIf you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Drug discovery is changing. Deep generative models, as being pioneered by our guest Dr. Alex Zhavoronkov, founder and CEO of InSilico Medicine, are able to generate entirely new molecules and even, as we'll hear, can discover new targets altogether. Within days. This fall, InSilico and collaborators published an application of their generative reinforcement learning (GENTRL) to generate tens of thousands of novel compounds, synthesized only the 6 best, and identified a selective and nanomolar-potent candidate among them. We discuss deep generative drug discovery models, promise and criticism on these new methodologies, and dive into new research from their pending publications on NASH and we hear about a breaking new contribution by the InSilico team regarding a potential treatment for CoronaVirus. This is the TomorrowScale Podcast. I'm Justin Briggs. Sources: “Deep learning enables rapid identification of potent DDR1 kinase inhibitors” (Zhavoronkov 2019) “Reply to: Assessing the Impact of Generative AI on Medicinal Chemistry” (Zhavoronkov 2020) https://insilico.com https://tomorrowscale.com The TomorrowScale Podcast was created by Justin Briggs to showcase scientists and entrepreneurs who are building the future, and hear stories about how to build the future. The views expressed by the host and guests are their own, and the content of this show should not be considered legal, tax, or investing advice. Thank you to our guests for sharing their time and knowledge with us. Thanks for listening. Please science responsibly. --- Support this podcast: https://anchor.fm/tomorrowscale/support

Quentin Vanhaelen is the Director of the Virtual Human Project at Insilico Medicine, a startup that has achieved a Series B funding for about $37 Million USD. They are using artificial intelligence and deep learning to identify bio markers in the human DNA to help aging research and medicine discovery that can help us extend longevity in the human race. Quentin has a Bachelor's & Masters degree in Physical Sciences and a PhD in Philosophy and Theoretical Physics, he's originally from Belgium he joins us today from Moscow to discuss the theories of aging, artificial intelligence and the applications to discover new techniques that can help us to discover more about aging and medicine. Click here to get resources and more info on this interview: https://www.rodrigoflamenco.com/Quentin-Vanhaelen-Insilico/ About Rodrigo Flamenco: Rodrigo flamenco started in a third world Country called El Salvador in Central America with no idea how to do businesses earning $600 a month on an IT job while on a $20K+ debt. After taking a couple of courses he decided to start his own business called Epic Web Studio, which ended working with many big international brands and over 18+ countries all over the world. Then an opportunity arrived to start a new business and for 2 years, without a website or even a name, that business won two $30K projects, one $55K project and connected with many of the top professionals and business and founders in the industry of animation. That business is now Frame Freak Studio which is his 100% focus. Now he helps other business (specially tech startups) to get better results through animations and helping professionals in the animation industry through teaching marketing. About Level Up! Your Business, Life & Mind: Level Up! is a series of interviews featuring successful professionals from all over the world who are making a mark in their lives and others and finding out how they did it so you can learn from the very best. Our interviews will be focused on finding out their principles, strategies, mindsets, habits and tools that you can use and implement in your business, life and mind to get to the next level of your goals. Join Our Business Community! http://www.rodrigoflamenco.com/ SUBSCRIBE! http://www.framefreakstudio.com/youtube Podcast: https://www.rodrigoflamenco.com/podcast/ Facebook: https://www.facebook.com/RodrigoeFlamenco/ Instagram: https://www.instagram.com/rodrigoeflamenco/ Linked In: https://www.linkedin.com/in/rodrigoflamenco/ Twitter: https://twitter.com/RodrigoFlamenco If you want to see better quality of videos please support us by becoming our Patron and help us bring you more amazing videos. https://www.rodrigoflamenco.com/patreon --- Send in a voice message: https://anchor.fm/level-up-business/message

Fedor Galkin, Project Manager at Insilico Medicine, Inc., discusses his work studying the microbiome, human genotypes, and aging/longevity. Galkin graduated from Moscow State University with a degree in Bioengineering & Bioinformatics. His work focuses on human microbiome aging clocks based on deep learning. Interestingly, the microbiome can serve as an incredibly accurate biological clock, able to predict the age of many people within just years. Galkin discusses the earliest microbiome aging clocks and recent advances, and the technology that is behind them. Some of these technologies can make assessments based on an individual's blood biochemistry and gene expression levels, etc., but as he states there has never before been a clock that predicts age based on gut microbes. Galkin discusses their work in detail, discussing how they select and look at the microbes. Galkin explains the correlations and organization in the microbes, and how with age, things fluctuate. He details how they observe the changes that show age, and how certain conditions, such as diabetes will make the gut microbes appear as a much older person. Continuing, the bioengineering expert talks about nutrients, and how supplements, etc. can impact the biological systems. And he explains how their work on the species level is ongoing, but that they hope to delve deeper into the functional and genetic level as well, in their continued study of the human microbiome. In this podcast: What is a microbiome aging clock? How nutrients play a role in the gut microbiome The role of supplements in biological health

Ira Pastor, ideaXme longevity and aging ambassador and founder of Bioquark, interviews Dr. William Pruett, from the Physiology and Biophysics Department, of the University of Mississippi Medical Center. Ira Pastor Comments: The year is now 2019, and we have surpassed $7 trillion in total annual healthcare expenditures around the globe. As part of that $7 trillion, we’re now spending close to a $1 trillion a year on pharmaceutical products. As we’ve been watching the traditional pharma product basket change over the last century, form small organic molecules drugs and vaccines, to larger macromolecule biologics (proteins and antibodies), and now into an era of gene and cell therapies, and other therapeutic modalities, the tools that allow these discoveries and development of these novel interventions have been changing as well. A set of tools that we have been hearing quite a bit about (and that we have discussed a bit on the show) in recent years is the triad of artificial intelligence, machine learning, and deep learning and their respective applications in the drug discovery and development processes. And a term we have heard a lot mentioned alongside these tools is that of “In-Silico” - an expression meaning "performed on computer" or "via computer simulation" in reference to different biological experiments. We’ve talked about a few of these applications on past shows, in terms of using some of these tools to better guide the rational drug design process, or more appropriately select patients for a clinical trial, via personalized medicine. But we have yet to address the "800-pound gorilla" in the room, and that is that even after you have your "perfect" drug candidate and your "perfect" inclusion / exclusion criteria, traditional clinical trials still cost billions of dollars and take many years of hard work, with no guarantee that your new drug will make it through the complexity that is represented by the human body, with its 30 trillion cells, its endless array of heterogenic micro-environments, wide range of gene expression, and so forth. But what if this wasn’t the case in the future? What if it was possible to conduct "In-Silico" clinical trials on virtual bodies that could perfectly mimic human physiology? Today we are joined by Dr. William Pruett, from the Physiology and Biophysics Department, of the University of Mississippi Medical Center. With a Doctorate in Mathematics from Baylor University, Dr. Pruett has been merging his skills from Mathematics (including expertise in representation theory, geometry, combinatorics, numerical analysis and algorithms) with an in-depth understanding of cardiovascular, renal, and endocrine physiology. Dr. Pruett’s research interests include the use of physiological modeling to generate hypotheses and to understand integrative physiological mechanisms that are not observable in either whole animal or human experiments. For almost 50 years, his department has been developing computer simulations of integrative physiology for both research and educational purposes. The current model, HumMod, is comprised of 14 organ systems, and includes neural, endocrine, circulatory, and renal physiology. HumMod provides a top-down model of human physiology from whole organs to individual molecules. It features more than 1,500 equations and 6,500 variables such as body fluids, circulation, electrolytes, hormones, metabolism, and skin temperature. HumMod aims to simulate how human physiology works and is currently the most sophisticated mathematical model of human physiology ever created. On this show we will hear from Dr. Pruett: How he became interested in mathematics, physiology, and in merging the two together. An overview of Hummod and how it works. Hummod's use in understanding renal physiology and pathophysiology of hypertension. Other therapeutic indications he and his partners are working on. Finally, his future visions of In-Silico clinical trials. ideaXme is a global podcast, mentor programme and creator series. Mission: Move the human story forward!™ ideaXme Ltd.

The titan thought leader podcast discusses trends, & innovations through intriguing and insightful discussions with industry thought leaders in the biopharmaceutical industry. Episode 2 discusses the artificial intelligence in drug discovery and aging research with guest speaker, Andrei Zhavoronkov from Insilico Medicine.

Longevity, eternal youth or even immortality have been an aspiration in religion and culture throughout history. Today, people adopt all sorts of approaches to increase their wellbeing, delay aging and avoid diseases. Efforts are increasingly quantified with sensors, wearables, or even biohacking - interventions to influence body biology. The new hope for advancements in longevity is seen in artificial intelligence, which is becoming increasingly powerful. Alex Zhavoronkov has been researching the use of AI in aging for years. He is the CEO of Insilico Medicine, a Baltimore-based leader in the next-generation artificial intelligence technologies for drug discovery and aging biomarkers discovery. He truly is a well of knowledge - since 2012 he published over 130 peer-reviewed research papers and 2 books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Palgrave Macmillan, 2013). In this episode, he talks about the complexity of aging as a biological process, types of artificial intelligence and the role of AI in research advancements.   Some of his latest research articles include:  Blood Biochemistry Analysis to Detect Smoking Status and Quantify Accelerated Aging in Smokers - https://www.nature.com/articles/s41598-018-35704-w#author-information Artificial intelligence for aging and longevity research: Recent advances and perspectives - https://www.sciencedirect.com/science/article/pii/S156816371830240X?via%3Dihub Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry - https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.8b00930 Listen also:  F013 What to expect from artificial intelligence in healthcare in the next 10 years? (Sally Daub, Enlitic) https://medium.com/faces-of-digital-health/f013-what-to-expect-from-artificial-intelligence-in-healthcare-in-the-next-10-years-fdaf2edf32f8

Artificial intelligence offers the promise of better health, faster drug discovery and testing, to create improved medical outcomes for patients. We talk with a world expert on using AI in life sciences to discover and develop drugs faster and less expensively.

Artificial intelligence offers the promise of better health, faster drug discovery and testing, to create improved medical outcomes for patients. We talk with a world expert on using AI in life sciences to discover and develop drugs faster and less expensively.

In today's episode, Kyle chats with Alexander Zhebrak, CTO of Insilico Medicine, Inc. Insilico self describes as artificial intelligence for drug discovery, biomarker development, and aging research. The conversation in this episode explores the ways in which machine learning, in particular, deep learning, is contributing to the advancement of drug discovery. This happens not just through research but also through software development. Insilico works on data pipelines and tools like MOSES, a benchmarking platform to support research on machine learning for drug discovery. The MOSES platform provides a standardized benchmarking dataset, a set of open-sourced models with unified implementation, and metrics to evaluate and assess their performance.

Insilico Medicine is working to harness artificial intelligence to address diseases of aging and in the process reinvent the way new drugs are discovered and developed. Its AI platform is integrated into the continuum of the discovery and development process and seeks to improve target identification, the selection of drug candidates, and predict clinical trial outcomes. In addition to working in collaboration with the large pharmaceutical companies, Insilico is pursuing internal drug discovery programs in range of diseases of aging. We spoke to Alex Zhavoronkov, CEO of Inisilco Medicine, about the company's platform technology, the potential for AI to transform the discovery and development of drugs, and why Insilico focuses its efforts on diseases of aging.

QCR Global Group is a niche life science management consulting firm, hosting thought leaders on an array of topics in industry. With a primary mission of, providing enlightened academic exchange with change innovators to maximize the cross professional understanding of methods while improving the exchange of information that benefits industry experts and their consumers. Hosted by Dr. D. Orozco, President of the Life Science Practice and Principal Manager at QCR, each thought leader provides a quick explanation of what he/she specializes in, challenges and benefits based on case representation, along with insightful strategies from their angle of the profession.

QCR Global Group is a niche life science management consulting firm, hosting thought leaders on an array of topics in industry. With a primary mission of, providing enlightened academic exchange with change innovators to maximize the cross professional understanding of methods while improving the exchange of information that benefits industry experts and their consumers. Hosted by Dr. D. Orozco, President of the Life Science Practice and Principal Manager at QCR, each thought leader provides a quick explanation of what he/she specializes in, challenges and benefits based on case representation, along with insightful strategies from their angle of the profession.

What would a biohacked future look like ? What would stop Supervillians creating seceret labs ?  Who polices the Cyborgs ? What is the controversial 5th pillar of biohacking ? Doctor Karl and Australia's most famous biohacker discuss.

Imagine visiting a doctor in the not too distant future. Afterwards she sends off data to a local gene lab to give your body a small upgrade. This is the world of biohacking. A place where biololgy is being controlled and shaped to our will - just like we have mastered computers. This episode bounces from In-Vivo to In-Silico and back again, visits the Last Universal Common Ancestor and involves a real human cyborg. Doctor Karl and Mr Meow Meow (Australia's most famous biohacker) explain this brave new world. Part One of a two part podcast.

    Alex Zhavoronkov, PhD, is a head of the Regenerative Medicine Laboratory at the Federal Clinical Research Center for Pediatric Hematology, Oncology and Immunology in and the adjunct professor of the Moscow Institute of Physics and Technology. He is also a director and trustee of the Biogerontology Research Foundation, a UK-based registered charity supporting  aging research worldwide and a director of the International Aging Research Portfolio (IARP) knowledge management project. He is the CEO or Insilico Medicine, Inc, a Baltimore-based company with research facility on the campus of the Johns Hopkins University Emerging Technology Centers. The company is focusing on signaling pathway activation analysis, drug discovery and drug repurposing for aging and age-related diseases. He also heads NeuroG, a neuroinformatics project intended to assist the elderly suffering from dementia. His primary research interests include systems biology of aging, regenerative medicine, next-generation  sequencing, molecular diagnostics and pathway analysis. He is the author of "The Ageless Generation: How advances in biomedicine will transform the global economy" (Palgrave Macmillan, 2013).  He holds two Bachelor Degrees from Queen’ s University, a Masters in Biotechnology from Johns Hopkins University, and a PhD in Biophysics  from the Moscow State University.

Årets tredje udgave af SAMDATA podcasten byder på to indslag, foruden SAMDATA nyheder, en kort opsamling af, hvad der er sket siden sidst og et tip fra Jeppe Engell. Til forskel fra de to forrige, er der i denne podcast ingen gæster i studiet. I stedet bringer vi først et indslag fra journalist Ernst Poulsen, der interviewer CTO Martin Nebelong Olsen, Bureauchef Anders Bisgaard og adm. direktør Andreas Iversen fra søsterfirmaerne In2media og Insilico. Emnet er den altid pågående diskussion om HTML versus native app til smartphones og tablets. Herefter har Esben Hardenberg snakket med Jesper Boeg fra firmaet Agile Upgrade. Jesper har stor erfaring med agil procesoptimering, hvilket derfor naturligt nok også er emnet for den lange snak. Da der optræder en del fagudtryk, har vi samlet en miniordbog - primært med links til Wikipedia - der giver forklaring. Den finder du nederst i shownoterne. Afslutningsvis fortæller Jeppe Engell om SAMDATA nyheder, samt giver et bogtip.  Kommentarer, ris/ros er som altid velkomment, om indhold til jeppe.engell@hk.dk og om teknik/produktion til esben@mememaker.com. Indhold 00:00:00 - 00:03:32 Velkommen og siden sidst 00:03:32 - 00:13:39 To App or not to App 00:13:39 - 00:16:09 Om SAMDATA Magasinets nye website og intro til indslaget om agil procesoptimering 00:16:09 - 01:03:08 Interview med Jesper Boeg, om agil procesoptimering og Scrum 01:03:08 - 01:08:49 Nyheder fra SAMDATA og bogtip fra Jeppe Engell Links TR Portræt med Christian Kragh, statens it Insilico In2Media Peytz & Co SAMDATA magasinets website Penetration Testing II,III og IV (Aarhus) Hacker træning weekend, 9-10 maj (København) Capture the Flag m. Henrik Kramshøj, 29-30 maj (København) Louise Meldgaard Bruun - Saml Tankerne Agile upgrade Jesper Boeg - Priming Kanban Jesper Boeg - Real Life Scrum Agile Upgrade blog Toyota Kata - Mike Rother Seven Habits of Highly Productive People Kanboard   Agil/Scrum ordbog og links Agil systemudvikling Lean softwareudvikling Trifork Vandfaldsmodellen Stage-gate modellen Sprint Sprint retrospective Donald G. Reinertsen - The Principles of Product Development Flow Scrum Det agile manifest Scrum produktejer Scrum Master Ceremonier/Meetings Dagligt standup møde Produkt Backlog Sprint backlog Business agility Change management Timebox Personal Kanban Story Points/Planning Poker Net promoter score

Join Designing Worlds hosts Saffia & Elrik for a grand tour of the dark and beautiful city of Insilico. Designing Worlds

Are designer molecules poised to take us into a new chemical dimension? This week, we explore how, long before the bunsen burner gets lit, computer aided chemistry can enable us to create in silico imaginary new molecules, reactions and designer catalysts. We also delve into how chemicals are manufactured on a massive scale with a visit to a plant making zeolites. And in the news, how hydrogen-metabolising bugs can supercharge deep-sea mussels, how reprogrammed immune system cells can hunt-down cancer, and nature's stock exchange - how plants and fungi develop a subsoil free-market economy... Like this podcast? Please help us by supporting the Naked Scientists

Are designer molecules poised to take us into a new chemical dimension? This week, we explore how, long before the bunsen burner gets lit, computer aided chemistry can enable us to create in silico imaginary new molecules, reactions and designer catalysts. We also delve into how chemicals are manufactured on a massive scale with a visit to a plant making zeolites. And in the news, how hydrogen-metabolising bugs can supercharge deep-sea mussels, how reprogrammed immune system cells can hunt-down cancer, and nature's stock exchange - how plants and fungi develop a subsoil free-market economy... Like this podcast? Please help us by supporting the Naked Scientists

En el episodio 19 de In Silico conversamos sobre OpenSocial, un proyecto de código abierto promovido por Google y adoptado por muchas de las principales redes sociales del mundo. Con OpenSocial puedes desarrollar aplicaciones para redes sociales usando HTML, Javascript y un único API. ¿Qué es OpenSocial? La Web es social. Aplicaciones y contenedores OpenSocial. Porqué OpenSocial es útil para los desarrolladores de aplicaciones sociales. Shindig, un proyecto de Apache para crear tu propio contenedor OpenSocial. Lleva tus conocimientos de Javascript al siguiente nivel: Javascript: The Good Parts, por Douglas Crockford, el arquitecto principal de Javascript en Yahoo. Recordando a Maniac Mansion y una versión de Maniac Mansion para descargar. Se acerca Google Wave. En vídeo La versiones solo audio y vídeo para iPod a continuación. Solo audio Si prefieres escuchar utiliza el siguiente reproductor. This div will be replaced var s1 = new SWFObject('http://www.ventanazul.com/sites/all/mediaplayer/player.swf','ply','480','20','9','#ffffff'); s1.addParam('allowfullscreen','true'); s1.addParam('allowscriptaccess','always'); s1.addParam('wmode','opaque'); s1.addParam('flashvars','file=http://blip.tv/file/get/Alexisbellido-OpenSocial337.mp3'); s1.write('mediaspace19'); Descargas audio (mp3) vídeo para iPod, iPhone o Touch (m4v)

En el episodio 17 de In Silico: ¿Ha llegado al fin la revolución de los libros digitales? Mientras Amazon lanza el nuevo Kindle DX compañías como Bookeen y Plastic Logic preparan nuevos modelos de sus lectores de libros digitales, también basados en E-Ink. Modelos de distribución en la Red y los servicios de imprenta en demanda de Lulu. ¿Qué titulos nos faltan en versiones digitales? En vídeo La versiones solo audio y vídeo para iPod a continuación. Solo audio Si prefieres escuchar utiliza el siguiente reproductor. This div will be replaced var s1 = new SWFObject('http://www.ventanazul.com/sites/all/mediaplayer/player.swf','ply','480','20','9','#ffffff'); s1.addParam('allowfullscreen','true'); s1.addParam('allowscriptaccess','always'); s1.addParam('wmode','opaque'); s1.addParam('flashvars','file=http://blip.tv/file/get/Alexisbellido-PublicacinYVentaDeLibrosEnInternet147.mp3'); s1.write('mediaspace17'); Descargas audio (mp3) vídeo para iPod, iPhone o Touch (m4v)

Mientras preparábamos un suculenta pizza en casa Beatriz me contó un poco más sobre el fascinante LittleBigPlanet, uno de los juegos más entretenidos que hemos jugado recientemente en el Playstation 3. Con ustedes, In Silico 16. En vídeo La versiones solo audio y vídeo para iPod a continuación. Solo audio Si prefieres escuchar utiliza el siguiente reproductor. This div will be replaced var s1 = new SWFObject('http://www.ventanazul.com/sites/all/mediaplayer/player.swf','ply','480','20','9','#ffffff'); s1.addParam('allowfullscreen','true'); s1.addParam('allowscriptaccess','always'); s1.addParam('wmode','opaque'); s1.addParam('flashvars','file=http://blip.tv/file/get/Alexisbellido-LittleBigPlanet746.mp3'); s1.write('mediaspace16'); Descargas audio (mp3) vídeo para iPod, iPhone o Touch (m4v)

Luego de algunos meses probando muchos servicios de vídeo en la Web decidí dedicarle el episodio 15 de In Silico, en vivo, a contarles cómo me fue con cada uno de ellos y las posibilidades que existen para quienes quieren producir y distribuir vídeo por Internet. En este episodio hablamos sobre: YouTube. Vimeo. Viddler. Dailymotion. Blip.tv. Edición de vídeo con software libre: Kdenlive. Modelos de negocios y vídeo en la Web. Un rápido vistazo al nuevo Kindle DX. El vídeo La versiones solo audio y vídeo para iPod a continuación. Solo audio Si prefieres escuchar utiliza el siguiente reproductor. This div will be replaced var s1 = new SWFObject('http://www.ventanazul.com/sites/all/mediaplayer/player.swf','ply','480','20','9','#ffffff'); s1.addParam('allowfullscreen','true'); s1.addParam('allowscriptaccess','always'); s1.addParam('wmode','opaque'); s1.addParam('flashvars','file=http://blip.tv/file/get/Alexisbellido-VdeoEnLaWeb473.mp3'); s1.write('mediaspace15'); Descargas audio (mp3) vídeo para iPod, iPhone o Touch (m4v)

¿De qué sirve un negocio en la Red si no podemos recibir pagos? En la segunda parte de mi conversación sobre negocios virtuales con Beatriz comparto algunas ideas sobre cómo el dinero cambia de manos en Internet. En vídeo La versiones solo audio y vídeo para iPod a continuación. Solo audio Si prefieres escuchar utiliza el siguiente reproductor. This div will be replaced var s1 = new SWFObject('http://www.ventanazul.com/sites/all/mediaplayer/player.swf','ply','480','20','9','#ffffff'); s1.addParam('allowfullscreen','true'); s1.addParam('allowscriptaccess','always'); s1.addParam('wmode','opaque'); s1.addParam('flashvars','file=http://blip.tv/file/get/Alexisbellido-ProcesandoPagosPorInternet559.mp3'); s1.write('mediaspace14'); Descargas audio (mp3) vídeo para iPod, iPhone o Touch (m4v)

Muchos aún no entienden cómo funcionan los negocios virtuales. En este episodio le explico a Beatriz cómo crear negocios y hacer dinero en la Red, si ella lo entiende estoy seguro que muchos allí afuera también lo harán. En vídeo La versiones solo audio y vídeo para iPod a continuación. Solo audio Si prefieres escuchar utiliza el siguiente reproductor. This div will be replaced var s1 = new SWFObject('http://www.ventanazul.com/sites/all/mediaplayer/player.swf','ply','480','20','9','#ffffff'); s1.addParam('allowfullscreen','true'); s1.addParam('allowscriptaccess','always'); s1.addParam('wmode','opaque'); s1.addParam('flashvars','file=http://blip.tv/file/get/Alexisbellido-NegociosVirtuales588.mp3'); s1.write('mediaspace13'); Descargas audio (mp3) vídeo para iPod, iPhone o Touch (m4v)

La nueva gripe, la variedad A(H1N1), sirve de excusa para hablar un poco más sobre los beneficios del teletrabajo mientras el caos y la desinformación se apoderan de los medios sociales. Sí, otra vez Twitter. Además, algunos comentarios sobre edición de vídeo, servicios de vídeo en la Web y la participación del público. Todo esto en In Silico 12, grabado en vivo el 30 de abril de 2009. La versiones solo audio y vídeo para iPod a continuación. Solo audio Si prefieres escuchar utiliza el siguiente reproductor. This div will be replaced var s1 = new SWFObject('http://www.ventanazul.com/sites/all/mediaplayer/player.swf','ply','480','20','9','#ffffff'); s1.addParam('allowfullscreen','true'); s1.addParam('allowscriptaccess','always'); s1.addParam('wmode','opaque'); s1.addParam('flashvars','file=http://blip.tv/file/get/Alexisbellido-TeletrabajoGripeCaosEnTwitterYVdeoEnLaWeb105.mp3'); s1.write('mediaspace12'); Descargas audio (mp3) vídeo para iPod, iPhone o Touch (m4v) Los enlaces Puedes encontrar todos los enlaces mencionados en Delicious.

El primer programa en vivo, hablando con la audiencia sobre redes sociales, la nube, software libre y más. La versiones solo audio y vídeo para iPod a continuación. Solo audio Si prefieres escuchar utiliza el siguiente reproductor. This div will be replaced var s1 = new SWFObject('http://www.ventanazul.com/sites/all/mediaplayer/player.swf','ply','480','20','9','#ffffff'); s1.addParam('allowfullscreen','true'); s1.addParam('allowscriptaccess','always'); s1.addParam('wmode','opaque'); s1.addParam('flashvars','file=http://blip.tv/file/get/Alexisbellido-RedesSocialesYLaNube874.mp3'); s1.write('mediaspace11'); Descargas audio (mp3) vídeo para iPod, iPhone o Touch (m4v)

(Photo – Chris McKibbin | cmckibbinphotos.com) Since 2002, Electro-Aussie artisans PENDULUM, have been breaking down the barriers in mainstream electronic music to create a diverse audience that has landed the band on charts worldwide since the release of 2008’s “In Silico” (Atlantic/Warner). Friday (March 6th), ABORT Magazine’s Ninjoelspy chatted with founding members Rob “Sire of […]